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Then they came for me-- 
And there was no one left 
To speak out for me. 
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ABSTRACT 
 Aggregation of the microtubule associated protein tau (MAPT) into filamentous 
neurofibrillary tangles (NFTs) is a defining molecular hallmark of neurodegenerative 
diseases such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Despite 
the discovery of NFTs decades ago, the molecular mechanisms underpinning their 
formation and neurotoxicity have remained elusive. Recently, our lab has shown that 
stress granule (SG) associated RNA binding proteins (RBPs) co-deposit with pathological 
tau in mouse models and human disease; reduction of the SG associated protein TIA1 
also protects against tau-mediated behavioral deficits and degeneration. Here we 
demonstrate that RBPs facilitate tau pathogenesis and exhibit prominent signs of 
dysfunction early in disease. By immunoprecipitating pathological tau from the 
transgenic rTg4510 AD mouse model, we have found that tau associates with many RBPs 
and ribosomal subunits, and these associations change as tau pathology develops. These 
RBPs also become increasingly insoluble in tauopathy, consistent with the formation of 
fibrillar aggregates. We also show by immunohistochemistry that as tau forms mature 
neurofibrillary tangles, RBPs lose their interaction with tau and aggregate to the 
  ix 
periphery of the tangle in mouse and human tissue, suggesting that RBPs contribute to 
earlier stages of tau aggregation. Seeing this, we sought to determine at what point of tau 
pathogenesis RBPs become relevant to the disease process. Using the PS19 mouse line, 
which develops tangle pathology more slowly than the rTg4510, we have found that RBP 
immunohistochemistry is highly sensitive to tissue fixation methods, that different brain 
regions have unique localization patterns of canonically nuclear RBPs, and that 
transgenic tau mice show striking changes in hippocampal RBP regulation very early in 
tau pathogenesis. This precedes an eventual destabilization and disruption of the nuclear 
lamina. We further show that overexpression of TIA1 accelerates the somatodendritic 
accumulation of phosphorylated tau in vivo, and that TIA1 granules co-localize with 
granules of misfolded tau. Together these findings support the idea that ribonucleoprotein 
granules contribute significantly to early pathological tau formation and that 
misregulation of these proteins progresses in tandem with tau pathology. RBPs thus offer 
promising new therapeutic targets for Alzheimer’s disease and related tauopathies. 
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INTRODUCTION 
Adapted from Maziuk, Ballance and Wolozin. Frontiers in Molecular Neuroscience 2017 
 
 
Alzheimer’s disease clinical presentation and treatment options 
 Alzheimer’s disease (AD) is a chronic neurodegenerative condition characterized 
by progressive brain atrophy and loss of cognition (Alzheimer’s Association, 2019) 
(Bondi, Edmonds, & Salmon, 2017). Clinically this presents as an initial difficulty with 
short term memory tasks which progresses into disorientation, mood swings, problems 
with language, and eventual full cognitive decline until death (Atri, 2019). Currently, AD 
is ranked as the sixth leading cause of death in the United States overall, though this 
increases to the third leading cause of death in individuals 65 years of age or older 
(Alzheimer’s Association, 2019). Approximately 6% of individuals over the age of 65 are 
affected by AD, and due to the increasing size of the population over 65 years of age, the 
prevalence of AD cases is expected to triple by 2050 (Alzheimer’s Association, 2019). 
However, no treatment options are currently available for the prevention or reversal of 
the disease; the only treatments currently available improve symptoms for a period of a 
few months. Consequently, AD currently represents an expensive public health crisis, as 
palliative care for AD patients can extend for many years (Alzheimer’s Association, 
2019). 
 AD is typically characterized by a loss of neurons in the hippocampus and 
entorhinal cortex of the temporal lobe which eventually progresses to degeneration 
throughout the parietal and frontal cortex (Karran, Mercken, & Strooper, 2011)  
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Figure 1: Typical pattern of tau protein misfolding in Alzheimer's disease 
Misfolded tau proteins occur first in the locus coeruleus and transentorhinal layer from which they spread 
to the transentorhinal region, the proper entorhinal cortex, and ultimately affect all interconnected 
neocorticalbrain regions. (Adapted from Fornari et al. 2019) 
 
 
(Y. Wang & Mandelkow, 2016) (Fig. 1). While recent advancements in medical imaging 
have improved the ability to diagnose the disease, the early stages of AD remain difficult 
to diagnose. Strong biomarkers have yet to be uncovered for highly accurate diagnosis 
and clinicians must rely on strict assessment criteria from the National Institute of 
Neurological and Communicative Disorders and Stroke (NINCDS) (Long & Holtzman, 
2019). 
  Once diagnosed, only five medications are currently on the market for AD 
treatment: four acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine, and 
donepezil) and memantine, and NMDA receptor antagonist (Weller & Budson, 2018). 
Reduction in cholinergic neuron activity is well established in AD brains, and these 
acetylcholinesterase inhibitors elicit minor improvements in the cognitive abilities in 
approximately 50% of mild to moderate AD patients for 6-12 months (P. Anand & Singh, 
2013). Glutamatergic excitotoxicity is another well-established feature of AD, and the 
NMDA receptor antagonist has shown mild efficacy in improving cognition in a subset of 
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AD patients for a brief period (R. Wang & Reddy, 2017). However, none of these 
therapies is effective in reversing or preventing disease progression, and without a 
significant breakthrough in AD therapeutics the cost of treatment and caregiving for AD 
patients is expected to exceed $1 trillion by 2050 (Alzheimer’s Association, 2019). 
Alzheimer’s disease etiology and progression 
 While the direct causes of AD remain poorly understood, the major 
neuropathologies and pattern of neuronal loss have been extensively characterized in AD 
brains. The AD brain can be defined by two major protein aggregates: extracellular 
plaques composed of amyloid-β (Aβ) protein and intraneuronal aggregates of the 
microtubule associated protein tau (MAPT, or tau) commonly referred to as 
neurofibrillary tangles (NFTs) (BrightFocus Foundation, 2019) (Fig. 2). AD can also be 
inherited in an autosomal dominant fashion by mutations in amyloid precursor protein 
(APP), presnilin 1 (PSEN1), or presenilin 2 (PSEN2) (Tanzi & Bertram, 2005). APP is a 
transmembrane holoprotein of largely unknown function which is expressed at neuronal 
synapses and cleaved into Aβ by the cleaving enzymes α or β secretase (BACE) followed 
by γ-secretase; PSEN1 and 2 form the catalytic site of γ-secretase (Steiner, Capell, 
Leimer, & Haass, 1999) (Karran et al., 2011) (O’Brien & Wong, 2011). These findings 
led to the formation of the amyloid cascade hypothesis of AD, which postulated that Aβ 
deposition in the brain was a crucial step in AD pathogenesis and ultimate caused AD 
(Fig. 3). This notion has been recently challenged by that fact that amyloid clearing 
antibody therapies including bapineuzumab and solanezumab have failed in Phase III 
clinical trials (Tayeb, Murray, Price, & Tarazi, 2013). It has also become clear that 
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amyloid burden in mice and in humans does not linearly correlate with AD development 
or cognitive decline (Braak & Braak, 1991). Thus, recent iterations of the hypothesis 
propose that soluble toxic oligomers of Aβ may account for the neurotoxicity and 
downstream effects of the peptide (Karran et al., 2011) (Tanzi & Bertram, 2005). 
 On the other hand, increasing evidence suggests that tau tangles and not amyloid 
plaques correlates more closely with disease (Matthews, 2006). Tau is normally a protein 
expressed in the axons of neurons where it binds to and regulates microtubules 
(Weingarten, Lockwood, Hwo, & Kirschner, 1975). Under healthy conditions, this 
binding is regulated by phosphorylation of tau at various sites by multiple kinases 
including GSK3β (Maqbool, Mobashir, & Hoda, 2016). In disease, tau becomes 
hyperphosphorylated, which promotes its complete dissociation from microtubules and 
accumulation as free diffuse tau in the cytoplasm. As free tau accumulates, it mislocalizes 
to the somatodendritic compartment of the neuron and aggregates into paired helical 
filaments (PHFs). These PHFs eventually aggregate further into the fibrillar tangles 
observed in the AD brain (Ballatore, Lee, & Trojanowski, 2007) (Fig. 4). Many 
neurodegenerative diseases other than AD are also identifiable by the formation and 
accumulation of NFTs with or without amyloid burden. These diseases include 
Frontotemporal Lobar Degeneration (FTLD), Corticobasal Degeneration, Progressive 
Supranuclear Palsy (PSP), and Chronic Traumatic Encephalopathy (CTE) (Iqbal, Liu, 
Gong, & Grundke-Iqbal, 2010). 
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Figure 2: Amyloid plaques and neurofibrillary tangles are molecular hallmarks of AD. 
The AD brain (right) contains two major molecular pathologies: extracellular plaques composed of 
amyloid-β (Aβ) peptide and intracellular aggregates known as neurofibrillary tangles (NFTs) composed of 
the microtubule associated protein tau (MAPT). Amyloid plaques are hard, insoluble accumulations of beta 
amyloid proteins which aggregate between neurons of AD patients; NFTs are twisted fibrils of 
hyperphosphorylated, misfolded tau which form inside neurons as disease progresses. (Image from the 
BrightFocus Foundation, https://www.brightfocus.org/alzheimers-disease/infographic/amyloid-plaques-
and-neurofibrillary-tangles). 
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Figure 3: The amyloid cascade hypothesis 
The amyloid cascade hypothesis posits that the deposition of the amyloid-β peptide in the brain 
parenchyma is a crucial step that ultimately leads to Alzheimer’s disease. Autosomal dominant mutations 
that cause early onset familial Alzheimer’s disease (FAD) occur in three genes: presenilin 1 (PSEN1), 
PSEN2 and amyloid precursor protein (APP). This hypothesis has been modified over the years as it has 
become clear that the correlation between dementia or other cognitive alterations and amyloid-β 
accumulation in the brain in the form of amyloid plaques is not linear, neither in humans nor in mice. The 
concept of amyloid-β-derived diffusible ligands or soluble toxic oligomers has been proposed to account 
for the neurotoxicity of the amyloid-β peptide. These intermediary forms lie somewhere between free, 
soluble amyloid-β monomers and insoluble amyloid fibrils, but the exact molecular composition of these 
oligomers remains elusive. Toxic, soluble amyloid-β in different forms has been isolated from transfected 
Chinese hamster ovary cells, transgenic mouse brains, the human brain or it has been reconstituted in vitro 
under various experimental conditions. The amyloid cascade hypothesis now suggests that synaptotoxicity 
and neurotoxicity may be mediated by such soluble forms of multimeric amyloid-β peptide species. The 
dynamic nature of these species and the poorly defined mechanism (or mechanisms) of toxicity make this 
topic particularly controversial in the field. Given this uncertainty, we prefer to use the term ‘aggregate 
stress’ to describe the potential mechanisms that may lead to amyloid-β aggregation, the formation of 
paired helical filaments (PHFs) of tau aggregates and, ultimately, result in neuronal loss. Aβ42, the 42-
amino acid form of amyloid-β. (Adapted from Karran, Mercken and De Strooper, Nat Rev Drug Discov 
2011) 
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Figure 4: A schematic representation of the different stages of the formation of pathological 
tau aggregates. 
a | Abnormal disengagement of tau from the microtubules (MTs) and a concomitant increase in the 
cytosolic concentration of tau are likely to be the key events that lead to tau-mediated neurodegeneration. 
Direct causes of abnormal disengagement of tau from the MTs include an imbalance of tau kinases and/or 
phosphatases, mutations of the tau gene, covalent modification of tau causing and/or promoting misfolding, 
and possibly other causes such as other post-translational modifications. b | Once tau is unbound from the 
MT it becomes more likely to misfold. This is thought to be a stochastic phenomenon that is more likely at 
higher cytosolic tau concentrations. c | Early deposits of tau, called 'pretangles', are not stained by congo 
red or thioflavine-T, indicating that these intermediate forms of aggregated tau do not exhibit the pleated b-
sheet structure typically found in amyloid aggregates. d | A structural transition leads to this more 
organized aggregate and the eventual development of neurofibrillary tangles (e). Such transitions may be 
facilitated by heterogeneous interactions with membranous structures. (Adapted from Ballatore, Lee and 
Trojanowski Nat Rev Neurosci 2007) 
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Tau structure, function, and mechanisms of aggregation 
 Under healthy conditions, tau is primarily found in neuronal axons where it 
functions to stabilize and control microtubule dynamics, cytoskeletal reorganization, and 
axonal transportation (Mandelkow & Mandelkow, 2012). Encoded by the MAPT gene, 
tau also exists in six isoforms in the adult human brain; these isoforms differ according to 
the inclusion of 0, 1 or 2 near-amino terminal inserts (0N, 1N, 2N respectively) and the 
inclusion of carboxy-terminal repeat R2 for either three or four total carboxy-terminal 
repeats (R3 or R4, respectively) (Y. Wang & Mandelkow, 2016) (Fig. 5). These varying 
isoforms display different propensities for microtubule binding, subcellular distribution, 
and aggregation, though the exact functions of particular isoforms remain to be 
elucidated. 
 Normally, tau exists as a disordered and natively unfolded protein with very high 
solubility and low tendency for aggregation (Ballatore et al., 2007). However, 
pathological tau, or tau which forms the PHFs evident in tauopathies, is known to have 
extensive post-translational modifications (PTMs). Hyperphosphorylation is a key feature 
of aggregate tau, with up to 45 phosphorylation sites observed experimentally (Y. Wang 
& Mandelkow, 2016); key sites include tyrosines 18 and 394, threonines 205 and 231, 
and serines 202, 214, 256, 262, 396, and 404. In addition, acetylation of tau has recently 
been identified at several lysine residues in aggregate tau (Cohen et al., 2011). This 
acetylation reduces tau turnover and promotes tau toxicity, suggesting it to be critical in 
the disease process. 
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Figure 5:The human MAPT gene and the splice isoforms of tau in the human brain  
MAPT, the gene encoding human tau, contains 16 exons. Exon 1 (E1), E4, E5, E7, E9, E11, E12 and E13 
are constitutive, whereas the others are subject to alternative splicing. E0 and E1 encode the 5ʹ untranslated 
sequences of MAPT mRNA, whereas E14 is part of the 3ʹ untranslated region. E0 is part of the promoter, 
which is transcribed but not translated. The translation initiation codon ATG is in E1. E4a, E6 and E8 are 
transcribed only in peripheral tissue. The six human brain tau isoforms are generated through alternative 
splicing of E2, E3 and E10. These tau isoforms differ according to the presence of 0, 1 or 2 near-amino-
terminal inserts (0N, 1N or 2N, respectively) and the presence of repeat R2, yielding 3 or 4 carboxy-
terminal repeat domain (3R or 4R, respectively) tau species. The expression of human tau is 
developmentally regulated: in the adult brain, six isoforms of tau are expressed, whereas in the fetal brain 
only the shortest tau is expressed. In the adult human brain, levels of the 3R and 4R forms are roughly 
equal and the 2N isoform is underrepresented compared with the others: the 0N, 1N and 2N tau isoforms 
comprise ~37%, ~54% and ~9% of total tau, respectively. The expression of tau in the human brain shows 
considerable regional variation. The mRNA and protein levels of tau in the neocortex are twofold higher 
than those in the white matter and cerebellum. The splicing of MAPT also exhibits regional differences; for 
example, the level of 0N3R tau is lower in the cerebellum than in other regions. This variation of tau 
expression may contribute to the differential vulnerability of brain regions to tau pathology.  (Adapted from 
Wang and Mendelkow, Nat Rev Neurosci 2016) 
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 These PTMs act to dissociate tau from microtubules, where it consequently 
accumulates and mislocalizes in the somatodendritic cytosol as diffuse tau. As it  
accumulates, it oligomerizes and eventually fibrillarizes to form mature NFTs, but the 
mechanisms behind this process remain unclear. While the previously mentioned tau 
hyperphosphorylation is a key feature of aggregate tau, phosphorylation alone is not 
sufficient to for tau aggregation (Y. Wang & Mandelkow, 2016). In vitro, tau aggregation 
can be induced by crowding reagents and polyanionic molecules such as heparin, dextran 
sulfate, or RNA regardless of its phosphorylation state (Kampers, Friedhoff, Biernat, 
Mandelkow, & Mandelkow, 1996) (Goedert et al., 1996). This may be through a 
stabilization of an aggregate prone conformation of tau; tau PTMs also promote disease 
associated conformational changes (Yuzwa, Cheung, Okon, McIntosh, & Vocadlo, 
2014), and so the conformation of the typically disordered tau protein may be the most 
relevant factor to its aggregation. 
 Since their discovery, NFTs have been studied and characterized as the major 
driver of neurodegenerative tauopathies. However, substantial recent evidence has 
emerged to challenge this notion and instead assert that soluble tau aggregates are more 
critical to disease pathogenesis. In 2005, Santacruz et al. demonstrated that reduction of 
soluble tau but not fibrillar tau rescued tau-mediated memory deficits and survival in a 
reversible mouse model of AD (Santacruz et al., 2005). Since then it has been shown that 
tau dimers and trimers are more toxic than either monomers or fibrils (Ward, 
Himmelstein, Lancia, & Binder, 2012), that tau oligomers propagate along neuronal 
projections in transgenic tau mice as they do in human patients (Lasagna-Reeves et al., 
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2012), that multiple neurotoxic strains of oligomers exist in human AD patients (Gerson, 
Mudher, & Kayed, 2016), that tau oligomers are associated with brain inflammation in 
transgenic tau mice (Nilson et al., 2016), and that tau oligomers instigate mitochondrial 
damage (Shafiei, Guerrero-Muñoz, & Castillo-Carranza, 2017). While it has become 
increasingly clear that tau oligomers are a central player in tau-mediated 
neurodegeneration, the mechanisms underlying their formation and accumulation are not 
yet established. The potential answer may lie in an exciting new area of 
neurodegenerative research in RNA binding proteins, which is discussed below.  
RNA binding proteins and their relevance to neurodegenerative disorders 
Over the past decade an increasing body of work investigating the unusual 
biology of RNA binding proteins (RBPs) has shed new insight into mechanisms of 
protein aggregation in disease (Li, King, Shorter, & Gitler, 2013). RBPs represent a class 
of over 800 proteins responsible for the regulation of mRNA maturation in the nucleus as 
well as mRNA translation in the cytoplasm (Fig. 6). The domain structure of these 
proteins typically includes RNA recognition motifs (RRMs), aggregation promoting low 
complexity domains (LCDs), and nuclear import and export sequences (Lunde, Moore, & 
Varani, 2007) (King, Gitler, & Shorter, 2012) (Espinosa Angarica, Ventura, & Sancho, 
2013) (Fig. 7). Importantly, RBPs form a variety of RNA-protein (RNP) granules that are 
critical for RNA metabolism; these granules include processing-bodies (P-bodies), stress 
granules (SGs), nuclear granules, and/or transport granules (N. L. Kedersha, Gupta, Li, 
Miller, & Anderson, 1999). P-bodies are responsible for mRNA silencing and 
degradation, while SGs function to suppress the translation of non-essential proteins in 
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favor of protective stress-response proteins. SGs are nucleated by a core set of RBPs (see 
below) with their associated transcripts, and maturation of the SG incorporates secondary 
RBPs, additional transcripts, and proteins that enable interactions with other organelles, 
such as microtubules, actin filaments, autophagosomes and mitochondria (Buchan & 
Parker, 2009) (Vanderweyde et al., 2016).  
 RBPs share important genetic and pathological links with neurological diseases 
(Table 1). Tar DNA binding protein (gene, TARDBP; protein, TDP-43) is the primary 
component of pathological aggregates in most cases of ALS as well as the 40% of cases 
of FTLD associated with progranulin haplo-insufficiency; in addition, mutations in 
TARDBP cause familial ALS. As described in Table 1, mutations in FUS, hnRNPA1/B2 
and other RBPs are associated with familial forms of motor neuron disorders, while 
mutations in the genes encoding these proteins are associated with formation or removal 
of RNA granules cause ALS, FTLD, other motor neuron diseases as well as myopathies. 
Recent studies from our laboratory also implicate RBPs such as T-cell intracelluluar 
antigen 1 (TIA1) in the pathophysiology of AD and other tauopathies (Vanderweyde et 
al., 2012) (Vanderweyde et al., 2016). Histopathological studies also implicate RBPs in 
Huntington’s Disease (HD), and Creutzfeldt-Jakob Disease (CJD). These discoveries 
have propelled extensive efforts to understand how dysregulation of RBP aggregation 
leads to neurodegenerative conditions. 
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Figure 6: RNA binding proteins (RBPs) act on RNA to regulate a variety of processes. 
An RNA-binding protein (RBP) can interact with RNA through defined RNA-binding domains to regulate 
RNA metabolism and/or function. For example, RBPs can promote mRNA stability, be responsible for 
mRNA transport and localization, or be involved in mRNA splicing, transcription or translation. (Adapted 
from Hentze et al. Nat Rev Mol Cell Biol 2018) 
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Figure 7: Structures of RNA binding proteins 
RNA binding proteins, such as TIA-1, TDP-43 and FUS, contain RNA-recognition motifs (RRM), which 
bind RNA and Glycine rich (Gly-rich) domains that mediate protein aggregation. TDP-43 and FUS contain 
discrete nuclear localization and nuclear export signals (NLS, NES), while nuclear localization of TIA-1 
does not appear to localize using a particular domain. (Adapted from Wolozin, Mol Neurodegener 2012) 
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RNA Binding Protein Abreviation Associated Diseases 
TAR DNA-binding protein 43 TDP43 ALS*^, FTLD*^, 
AD^, HD^ 
T-cell intracellular antigen 1 TIA1 ALS^, FTLD^, AD^ 
Ras GTPase-activating protein-binding 
protein 1 
G3BP1 ALS^, FTLD^, AD^ 
Tristetraprolin TTP ALS^, FTLD^, AD^ 
Fused in Sarcoma FUS ALS*^, FTLD*^ 
Ewing Sarcoma Protein EWS ALS*^, FTLD*^ 
TATA-Box Binding Protein Associated 
Factor 15 
TAF15 ALS*^, FTLD*^ 
Heterogeneous Ribonucleoprotein Particle 
A1/A2 
hnRNPA1/A
2 
ALS*, FTLD* 
Angiogenin ANG ALS, PD* 
Survival of motor neuron SMN1 ALS*, SMA* 
Matrin-3 MATR3 ALS^ 
Ataxin-2 ATXN2 ALS^ 
Optineurin OPTN ALS*^ 
Fragile X mental retardation protein  FMRP FXS*  
*Mutations linked to disease 
^Inclusions linked to disease 
Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Dementia (FTLD), 
Alzheimer's Disease (AD), Huntington's Disease (HD), Parkinson's Disease (PD), 
Fragile X Syndrome (FSX), Spinal Muscular Atrophy (SMA) 
Table 1: RNA binding proteins implicated in neurodegenerative disorders 
*Mutations linked to disease 
^Inclusions linked to disease 
Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Lobar Dementia (FTLD), Alzheimer's Disease 
(AD), Huntington's Disease (HD), Parkinson's Disease (PD), Fragile X Syndrome (FSX), Spinal Muscular 
Atrophy (SMA) 
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Stress Granules and P-bodies 
SGs and P-bodies are key RNP granules that transiently consolidate cytoplasmic 
mRNAs. SGs form rapidly with cellular stress; stress kinases phosphorylate translation 
initiation factor eIF2α, which promotes polysome disassembly and SG formation (N. L. 
Kedersha et al., 1999). Some of the core SG nucleating RBPs include TIA1 (T-cell 
intracellular antigen 1), nucleolysin (TIAR), tristetraprolin (TTP), fragile X mental 
retardation protein (FMRP) and Ras-GAP SH3 Binding Protein 1 (G3BP1). Aggregation 
of these core nucleating proteins to form SGs initiates a process in which mRNAs stalled 
in translation are sequestered, allowing RNA translation to shift towards synthesis of 
cytoprotective proteins (Anderson & Kedersha, 2008) (Fig. 8). P-bodies associate with 
SGs and exchange transcripts which are subject to decapping and degradation (for 
detailed review on RNP granule components and dynamics, see Protter & Parker, 2016).  
RNP granules are dynamic, diverse structures, containing a variety of RBPs, 
enzymes, remodeling proteins, and transcripts (Protter & Parker, 2016). The nucleating 
components of RNP granules can differ based on environmental conditions, the 
mechanisms controlling granule formation, and cell type. SGs also evolve with time, 
moving from small primary stress granules to larger secondary stress granules 
(McDonald et al., 2011); further evolution might occur as mature stress granules become 
persistent pathological stress granules over the months to years associated with human 
disease. 
 Initial evidence implicating stress granules in neurodegenerative diseases arose 
from the seminal discovery that TDP-43 is the primary pathological protein that  
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Figure 8: A speculative model for mRNP transitions, particularly during stress 
Dashed arrows indicate possible destination of exported nascent transcripts. Wavy purple lines represent 
microtubules and their possible contribution of dynein/kinesin-mediated motorized transport to granule 
aggregation, and/or movement of mRNPs between different mRNP states. (Adapted from Buchan and 
Parker, Mol Cell 2009) 
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accumulates in sporadic ALS and many cases of FTD (Neumann et al., 2006). Following 
this discovery, ALS-linked mutations were identified in genes encoding multiple RBPs, 
including TDP-43, FUS, ATXN2, hnRNPA1, EWSR1 and TAF15 (Table 1). The 
disease-linked mutations generally occur in sequences encoding the low complexity (LC) 
domains of these proteins, and these mutations increase the tendency of the proteins to 
aggregate; mutations in other ALS-linked genes also stabilize stress granule dynamics, 
including mutations in C9orf72, Valosin containing protein (VCP) and Cu/Zn Superoxide 
Dismutase (SOD1) (Buchan & Parker, 2009) (Gal et al., 2016) (Lee, Lee, & Trojanowski, 
2012) . 
Neuronal Transport RNP Granules 
 Neurons have a unique need for controlled transport of mRNAs because of their 
lengthy processes and their need for activity dependent translation at the synapse. These 
needs demand high expression levels of RNP transport granules in the somatodendritic 
arbor. Transport granules contain RBPs such as staufen, pamillo and FMRP; these 
granules play important roles in mRNA localization and activity-dependent translational 
control at the synapse (Protter & Parker, 2016). Transport granules might represent the 
sites where RBP dysfunction in disease is first evident. Studies of granule trafficking in 
living neurons show that disease-linked mutations in RBPs, such as TDP-43, produce 
granules that are innately larger and travel slower (Liu-Yesucevitz et al., 2014).  These 
larger, slower moving granules might be a nidus for disease pathology and provide one 
potential mechanism through which mutations in RBPs produce neuronal disease. 
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Nuclear RNP Granules 
 The nucleus is highly enriched for many RBPs which regulate aspects of 
transcription and early RNA maturation events including splicing, capping, or nuclear 
export. A variety of RNP granules organize these many critical functions, including 
coiled bodies, PML bodies, Cajal bodies, nucleoli, speckles, gems, and histone locus 
bodies (HLBs), but how nuclear RNP granule deficiency contributes to 
neurodegenerative disorders is poorly understood. Disease linked RBPs including FUS, 
EWS and TAF15 mediate a DNA damage response through the formation of an RNP 
granule around DNA breaks (I. Wang et al., 2014) (Kai, 2016). Dipeptide repeats 
produced by mutations in C9orf72 might also interfere with multiple nuclear functions 
(see below). In addition, RBP45 is an RBP present in ALS, FTLD and AD inclusions that 
is associated with nuclear splicing pathway, while transcriptomic studies from ALS 
patients have revealed trends in RNA editing errors and disease related differences in 
splicing alterations (Chew et al., 2015). Crosslinked immunoprecipitation (iCLIP) studies 
of TDP-43 and FUS indicate that TDP-43 exhibits a preference for binding long 
transcripts of neuron enriched proteins, and FUS appears to function as a marker for 
RNA polymerase elongation (Polymenidou et al., 2012). These studies highlight a 
potentially important role for nuclear RNA metabolism in ALS. 
C9orf72 and RNA Foci in ALS 
 Hexanucleotide repeat expansions in a non-coding region of the gene C9orf72 
(C9) produce pleotropic pathology that are a major cause of familial ALS, and also 
contribute to other neurological diseases. This mutant expansion was initially identified 
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and found to induce the formation of RNA foci from the sense strand of the C9 mRNA 
(DeJesus-Hernandez et al., 2011) (Renton et al., 2011). Through a non-canonical form of 
translation, mutant C9 also produces 6 different dipeptide repeats (DPRs) that accumulate 
as aggregates in diseased brains (Ash et al., 2013) (Mori et al., 2013). C9 pathology also 
exhibits nuclear to cytoplasmic translocation of TDP-43 and formation of TDP-43 
inclusions, pathologies which cause many problems (Lee et al., 2012). RNA foci 
resulting from mutant C9 transcripts recruit a large variety of RBPs (Mori et al., 2013), 
and DPRs appear to interfere with multiple functions, including those of the nucleolus, 
the nuclear pore and other RBPs (Kwon et al., 2014) (Jovicic et al., 2015). C9orf72 
repeats have been shown to affect stress granule formation in N2A cells and in cortical 
neurons using the response to protein synthesis inhibitors as a marker of stress granule 
function. The protein synthesis inhibitor puromycin allows the ribosome to run-off the 
mRNA, causing the accumulation of naked mRNA, which promotes stress granule 
formation; the protein synthesis inhibitor cycloheximide stalls ribosomes on mRNA, 
which hides the mRNA and inhibits stress granule formation. C9orf72 repeat foci co-
localize with TIA1 puncta in the cytoplasm in response to puromycin, but not in response 
to cycloheximide (Maharjan, Künzli, Buthey, & Saxena, 2016). Conversely, CRISPR 
mediated deletion of C9 in myotonic dystrophy patient-derived fibroblasts inhibits stress 
granule formation, while overexpressing C9 leads to stress granule formation in the 
absence of stressors. For a detailed review of the evolving research into the 
pathophysiology of C9 disease see the review by Todd and Petrucelli (2016). 
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RNA Binding Protein Pathophysiology in Neurodegenerative Disease 
Phase Seperation is the First Step to Fibrillarization  
A key feature of many RBP sequences is the presence of a “prion-like” low 
complexity domain enriched in uncharged polar amino acids (King et al., 2012). 
Typically, these sequences are at least 60 amino acids longs, are predicted to be 
intrinsically unfolded, and enable the replication of a particular protein conformation 
from one copy to another (Couthouis et al., 2011). The low complexity domains (LCDs) 
are also conducive to mathematical modeling based on glutamine and asparagine 
enrichment, and such modeling has shown that that many of the disease-linked RBPs are 
those which have the greatest tendency to aggregate (Michelitsch & Weissman, 2000) 
(Alberti, Halfmann, King, Kapila, & Lindquist, 2009) (Zambrano et al., 2015). 
  RBPs appear to form RNP granules through a process of liquid-liquid phase 
separation (LLPS) mediated by their low complexity domains (Lin, Protter, Rosen, & 
Parker, 2015). LLPS refers to a biochemical process which forms distinct, non-membrane 
bound complexes within the cytoplasm that behave in a manner analogous to oil droplets 
in an aqueous solution. LLPS is hypothesized to allow RNA granules to be particularly 
dynamic, so that they are sufficiently stable to facilitate processes such as RNA transport 
but also sufficiently tractable to interact with the surrounding cytosol and readily disperse 
when acted on by cellular disaggregases, chaperones or signaling mechanisms. Studies 
using recombinant proteins or cell lines indicate that the RBPs hnRNPA1 and FUS cycle 
through LLPS in a process that is dependent on the C-terminal low complexity domains 
(Molliex et al., 2015). Upon repetitive cycling, a small fraction of the protein misfolds to 
  
22 
form highly stable amyloids; disease-linked mutations in these proteins strongly increase 
the likelihood to form such amyloids, perhaps providing the basis for the persistent 
pathological inclusions that accumulate in ALS (Fig. 9) (Murakami et al., 2015). The 
biophysical mechanisms leading to TDP-43 pathology, though, are less clear (Johnson et 
al., 2009) (Liu-Yesucevitz et al., 2010) (Conicella, Zerze, Mittal, & Fawzi, 2016). While 
TDP-43 readily forms stable aggregates and stable stress granules in vitro and in cultured 
neurons, recombinant forms of TDP-43 do not readily form hydrogels or undergo LLPS, 
and ALS-associated mutations in TDP-43 might even disrupt phase separation and self-
interaction. 
 
Figure 9: Liquid-liquid phase separation contributes to RNP granule dynamics and 
eventual fibrillization. 
Within the cytosol, RNA binding proteins (RBPs) containing low complexity prion-like domains (LCDs) 
exist in an unaggregated state. Upon activating signaling cascades, the LCDs mediate weak aggregation 
through liquid-liquid phase separation, creating a distinct compartment enriched in RBPs, RNA and other 
associated proteins. Importantly, these ribonucleoprotein granules maintain the ability to exchange material 
with the cytosol while in this state, which allows them to carry out key mRNA regulating events. However, 
persistent aggregation over time or other pathological insults can drive these RBPs to further aggregate into 
compact, stable fibrils. In this model, the fibrillar forms of these granules can no longer exchange material 
with the surrounding cytosol and effectively trap their components in the granule. (Adapted from Maziuk, 
Ballance, and Wolozin Front Mol Neurosci 2017). 
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LLPS provides a compelling mechanistic link between the low complexity prion 
domains in disease related RBPs and the pathological aggregation of RBP nucleated 
granules. The simplicity of the experimental systems used for the studies described above 
provides powerful strengths as well as weaknesses. Use of purified recombinant proteins 
in in vitro studies allows rigorous analysis of the biophysical properties of the RBPs. 
Such studies might ultimately provide valuable insights into the mechanisms through 
which differing mutations can produce distinct disorders, such as is observed for the 
continuum of disease between ALS and FTD. However, these studies do not address two 
important issues. The first issue is that these studies miss the biological complexity of 
neurons, which have multiple levels of regulation provided by chaperones, post-
translational modifications, RNA, disaggregates, the autolysosomal system, as well as the 
deleterious effects of aging. The second issue is the question of whether more 
aggregation is good or bad. Multiple different studies suggest that oligomers are more 
toxic to neurons than large inclusions, such as PrP, polyQ aggregates, Aβ plaques or 
neurofibrillary tangles (Santacruz et al., 2005) . Conversely, large inclusions could be 
important for mechanisms of toxicity that arise as a loss of function due to sequestration 
of proteins, such as RBPs, in insoluble aggregates similar to stress granules or large 
nuclear inclusions. Thus, although LLPS provides an appealing mechanism to explain 
how aggregation might be initiated, care must be taken when considering how this 
paradigm might translate to the brain. 
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Tau Pathology Promotes the Formation of Insoluble RBP Aggregates 
The microtubule associated protein tau is a multi-functional protein that is 
natively disordered, aggregation prone, and can disrupt protein homeostasis through 
several known mechanisms. Notably, it has been shown that increased levels of 
pathological tau lowers protein synthesis in vitro and in vivo (Meier, Bell, Lyons, 
Ingram, et al., 2016) (Koren et al., 2019). Over-expression of P301L mutant tau in 
rTg4510 mice upregulates the protein kinase R-like endoplasmic reticulum kinase 
(PERK), leading to eIF2α phosphorylation, translation inhibition, and synapse loss 
(Meier, Bell, Lyons, Ingram, et al., 2016) (Vanderweyde et al., 2016). Inhibition of 
PERK ameliorates these deficits (Vanderweyde et al., 2016). Tau also affects protein 
translation through direct interaction with the ribosomes and RBPs. These interactions are 
both altered in AD, where association with RBPs is increased (Meier, Bell, Lyons, 
Ingram, et al., 2016). Tau also modulates trafficking of RNA granules, with retrograde 
trafficking affected more than anterograde motion (Vanderweyde et al., 2016).   
New evidence identifying a novel mechanism through which tau alters protein 
homeostasis indicates that tau interacts with TIA1, a core SG nucleating protein, and 
other RBPs (Fig. 10). Tau pathology increases somatodendritic localization of TIA1, 
which is predominantly nuclear in healthy or unstressed cells (Vanderweyde et al., 2016). 
Tau/TIA1 complex formation accelerates the dynamics of SG formation, increases SG 
size, and concomitantly escalates tau aggregation. Disease-linked mutations enhance the 
effects of tau on SGs, with P301L tau generating TIA1 SGs that are larger but fewer in  
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Figure 10: Colocalization of TIA-1 with tau pathology in the Alzheimer brain 
Frontal cortex from a subject with AD was probed with antibodies to tau (phospho-tau, CP-13, PHF-1; total 
tau, Tau-5, green) and TIA-1 (red). Nuclei are identified with DAPI (blue). Sections were treated with 
Sudan Black to quench endogenous fluorescence. Large inclusions containing TIA-1 colocalize with each 
of the markers of tau protein that were tested. (Adapted from Vanderweyde et al. J Neurosci 2012) 
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number than those formed in cells expressing WT tau (Vanderweyde et al., 2016). 
Extracellular tau aggregates also increase SG formation raising the possibility that tau 
propagation also contributes to formation of pathological SGs.  Tau also modifies the 
TIA1 interactome, where multiple RBPs including SNRNP70, EWSR1, TAF15, and 
several ribosomal proteins form complexes with TIA1 in a tau dependent manner 
(Vanderweyde et al., 2016). It is important to note that the effects of tau on SG dynamics 
are TIA1 specific; TDP-43 and FUS do not co-localize with tau, nor do the RBPs G3BP 
and TTP despite being core nucleating SG proteins (Vanderweyde et al., 2012). Thus, tau 
appears to selectively regulate SGs containing TIA1 as a core component. 
 The interaction of tau with SGs is a two way street that has important implications 
for disease mechanisms and possibly for disease therapy. The interaction of TIA1 with 
tau increases the tendency of tau to form sarkosyl insoluble aggregates and stabilizes tau 
dynamics (Vanderweyde et al., 2016).  This means that the interaction of tau with SGs 
and perhaps other RNA granules might be previously undiscovered mechanism 
propelling tau aggregation and tau-mediated neurodegeneration. Conversely, knock down 
of TIA1 in primary hippocampal neurons reduces levels of misfolded tau, prevents acute 
toxicity associated with expressing P301L tau (Vanderweyde et al., 2016). 
TIA1 Mediates Tau Toxicity and Propagation in Vivo 
Recent studies from our lab have also demonstrated that reduction of TIA1 levels 
in the PS19 mouse model of tauopathy is protective against behavior deficits and 
shortened lifespan (Apicco et al., 2017). Interestingly, this protection corresponds with a 
paradoxical increase in NFTs in the mouse brain, suggesting that these insoluble 
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aggregates are not the toxic tau species in the pathogenesis of AD; evidence continues to 
suggest that tau oligomers are more toxic than fibrils, and that TIA1 may act to promote 
or stabilize these oligomers. This is further supported by the finding that TIA1 is 
responsible for the propagation of toxic tau oligomers, but not fibrils, in vivo, and that 
only oligomer propagation elicited neurotoxic effects (Jiang et al., 2019) (Fig. 11).  
Targeting Stress Granule Formation and Clearance in Disease 
Stress Kinase Activation of eIF2α 
SG formation can be triggered by a variety of cellular stressors including heat or 
cold shock, osmotic shock, nutrient deprivation, reactive oxygen species (ROS), or the 
unfolded protein responses (UPR) (Buchan & Parker, 2009). These stresses activate 
stress kinases, which phosphorylate 40S-eukaryotic initiation factor 2 (eIF2α) and 
prevent further translation initiation. Non-phosphorylated eIF2α normally forms 
complexes with methionine tRNA and GTP as part of the RNA translation initiation 
complex (N. L. Kedersha et al., 1999). However, phosphorylation of eIF2α increases 
binding of eIF2α to eIF2B, which prevents the exchange of GDP for GTP and inhibits 
translation initiation (N. L. Kedersha et al., 1999). Phosphorylation of eIF2α is reversible 
through Growth Arrest and DNA Damage-inducible Protein 34 (GADD34), which is an 
adapter protein that recruits phosphatase Protein Phosphatase 1 (PP1). Dephosphorylation 
of eIF2α stimulates SG disassembly, which allows re-initiation of normal translation (N. 
L. Kedersha et al., 1999).  
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Figure 11: TIA1 reduction prevents tau propagation from the oligomeric tau fraction 
(Right) Representative images showing co-localization of TOMA2 (red) and TIA1 (green) in CA3 of PS19 
Tia1+/+ and PS19 Tia1+/− mouse brain, respectively, 3 months after injection in CA1 of saline or S1p. 
With the co-staining, total cell nuclei are stained with DAPI (blue). Scale bar 50 μm. (Left) Quantitative 
analysis of TOMA2 staining intensity of CA3 in PS19::Tia1+/+ and PS19::Tia1+/− mice, respectively. In 
PS19::Tia1+/+ mice, S1p VS saline, **p < 0.001; With S1p injection, PS19::Tia1+/− VS PS19::Tia1+/+, 
##p < 0.001. (Adapted from Jiang et al 2018, Acta Neuropath 2018) 
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There are four core stress activated kinases that phosphorylate eIF2α: Protein 
Kinase R (PKR), PKR-like/Pancreatic endoplasmic reticulum kinase (PERK), Heme-
Regulated Inhibitor (HRI), or General Control Non-derepressible 2 (GCN) 
(Taniuchi, Miyake, Tsugawa, Oyadomari, & Oyadomari, 2016). PKR is activated by 
double stranded RNA, enabling it to respond to viral infection (Taniuchi et al., 2016). 
PKR appears to respond to viral activation of the UPR, and perhaps because of this, PKR 
also responds to the presence of aggregated Aβ and prion protein (Goggin, Beaudoin, 
Grenier, Brown, & Roucou, 2008). PERK also responds to the accumulation of misfolded 
or aggregated proteins as part of the UPR. PERK is activated in multiple different models 
of neurodegeneration, including those caused by overexpressing PrP, TDP-43 and tau 
(Moreno et al., 2012) (Kim et al., 2014). PERK inhibition by inhibitors such as 
GSK20606414 restores translation and protects against degeneration in these models 
(Kim et al., 2014). Unfortunately, the clinical utility of PKR inhibitors might be limited 
by the risk that they will allow activation of latent viruses in elderly patients, while PERK 
inhibitors cause severe pancreatic toxicity (Yu et al., 2015). GCN2 is activated by 
nutrient deprivation, specifically the absence of essential amino acids, and by activation 
of the ubiquitin-proteasome system (UPS). GCN2 deletion protects against memory loss 
in a APP/PS1 mouse model, but not in a 5xFAD APP mouse model (Devi & Ohno, 
2013). HRI is activated by oxidative stress induced by osmotic, heat shock, or arsenite, 
but has yet to be studied directly in neurodegeneration (Lu, Han, & Chen, 2001). 
eIF2α Independent Inhibition of Translation Initiation 
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 Translation can also be stalled through eIF2α independent mechanisms acting 
directly on components of the ribosome, particularly the small subunit involved in 
preinitation complexes (N. Kedersha & Anderson, 2007). Activated eIF2α binds to 
mRNA, but needs to interact with the eIF4F complex for initiation of translation. The 
eIF4F complex consists of eIF4A, B, E and G, which bind mRNA through the RBP poly-
A binding protein (PABP). The role of the eIF4F complex in neurodegeneration has yet 
to be studied in detail, but its potential importance is evident when considering 
angiogenin, a protein with mutations associated with ALS and Parkinson’s disease (van 
Es et al., 2011). The ribonuclease angiogenin cleaves tRNAs, to produce tiRNAs (tRNA-
derived stress induced fragments). The 5’ ends of tiRNAs displace components of the 
pre-initiation complex including eIF4G and eIF4A from mRNA, and displace eIF4F from 
the m7G mRNA cap (Ivanov, Emara, Villen, Gygi, & Anderson, 2011). Mutations in 
eIF4G1 are also associated with familial Parkinson’s disease; in this case the mechanism 
might lie in inappropriate aggregation with α-synuclein, potentially leading to either a 
loss of eIF4F function or a gain of α-synuclein aggregation (Siitonen et al., 2013). These 
independent lines of genetic evidence suggest a role for the eIF4F complex in the 
pathophysiology of neurodegenerative disease. 
Stalled Translation Initiation Complexes 
 Stalling of translation through eIF2α dependent or independent pathways allows 
for disassembly of polyribosomes.  The determinant of SG formation lies in whether the 
ribosomes remain associated with the transcripts. Stalling caused by the protein synthesis 
inhibitor puromycin disassociates the ribosome, producing naked transcript and initiating 
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SG assembly. In contrast, treatment with the protein synthesis inhibitor cycloheximide 
leaves ribosomes associated with transcripts and prevents SG formation (N. L. Kedersha 
et al., 1999). Stalled translation initiation complexes contain components of the 40S small 
ribosomal subunit, including eIF4E, eIF4G, and eIF3, as well as PABP, a RBP that links 
eIF4 proteins to the mRNA.  SGs form when the stalled complex is bound by core RBPs, 
such as TIA1, TIAR, TTP or G3BP. The LCDs of these proteins are necessary for SG 
formation, likely because of the tendency of these LCDs to aggregate as described.  
Mutant TIA1 lacking an RNA binding domain inhibits the formation of stress granules, 
demonstrating the necessity of RNA binding for the formation of stress granules (N. L. 
Kedersha et al., 1999). As the SG matures, other RBPs are recruited, leading to the 
growth of the SG and the binding of a wider array of transcripts. 
Heat Shock Proteins 
 Heat shock chaperones (HSPs) play a key role in responding to many of the same 
cell stressors that induce stress granules. While stress granules sequester non-essential 
mRNAs in the cytoplasm, heat shock transcripts are still translated. HSPs reduce protein 
misfolding and target existing misfolded/aggregated proteins for degradation, protecting 
neurons from injury caused by the accumulation of misfolded/aggregated proteins.  
Binding of HSPs to the LCDs of RBPs reduces their aggregation propensity; binding to 
the disordered domains of proteins such as tau or α-synuclein reduces the assembly of 
these aggregation prone regions as well. Hsp27 interacts directly with tau, specifically 
hyper-phosphorylated tau and PHFs (Abisambra et al., 2010). Studies with recombinant 
proteins and in vivo indicate that Hsp27, along with Hsp90 and other chaperones, are 
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positively correlated with and promote maintenance of soluble tau in AD, and negatively 
correlated with oligomers and reduction of tau fibrils; hsp70 also enables tau solubility 
and tau interaction with microtubules (Abisambra et al., 2010). Whether tau association 
with stress granules and RBPs affects interaction with HSPs is unknown, but is an 
important outstanding question.  
 HSPs survey the proteome, and target misfolded proteins that must be degraded 
for ubiquitination. This process is crucial for clearance of misfolded tau, as aggregates 
containing both ubiquitin and tau occur in Alzheimer’s Disease and FTLD-U. This 
surveillance function is mediated by the interaction of Hsp70 with CHIP, an E3 ubiquitin 
ligase; Chip mutant mice exhibit increased tau pathology, while overexpression of CHIP 
has the opposite effect (Dickey et al., 2006). Ubiquitination becomes important in the SG 
cascade because it provides a major mechanism through which persistent SGs can be 
targeted for clearance through autophagy and the UPR. 
Ubiquitin, Autophagy and Stress Granules 
 The failure to appropriately clear protein aggregates contributes significantly to 
neurodegenerative diseases, which is apparent in protein catabolism genes linked to FTD, 
ALS, or myopathies; stress granules are also disassembled by components of the 
proteasome and autophagy/lysosmal degradation pathways (Buchan, Kolaitis, Taylor, & 
Parker, 2013). Mutations in the genes encoding SQSTM/p62, ubiquilin-2 and VCP are all 
associated with familial forms of ALS, FTD and myopathy (Deng et al., 2011). VCP is a 
disaggregase that functions in SG clearance, although it is a complicated molecule with 
many different activities (Buchan et al., 2013). P62/SQSTM and ubiquilin-2 both 
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function in identifying pathological aggregates, such as persistent pathological SGs, and 
targeting them for removal. Mutations in SQSTM likely interfere with its function in 
targeting ubiquitinated proteins, including tau, for proteasomal degradation. Other genes 
linked to ALS and FTD, such as Tmem106b, Chmp2b, Tbk1 and Optineurin, have 
functions as adapter proteins that recognize ubiquitin tagged proteins. GRN, Tmem106B, 
and Chmp2b are also necessary for lysosmal function in autophagy. 
Summary 
 The aggregation of tau and formation of neurofibrillary tangles (NFTs) is a 
critical feature of AD and related tauopathies. While the molecular mechanisms 
underlying this aggregation and tau-mediated cytotoxicity are unclear, emerging evidence 
points to tau oligomers as a critical toxic moiety. Furthermore, the formation of these 
oligomers and their cytotoxic effects have been inextricably linked to RBP and SG 
biology, but fundamental questions concerning the nature of these interactions remain. It 
is currently unknown if tau interacts with RBPs besides TIA1, at what point in disease 
progression these interactions are most relevant, and the downstream effects these 
interactions have on overall mRNA metabolism in neurons. Because of their targetability 
through a variety of pathways, RNP granules serve as an attractive new therapeutic area 
in tauopathies in other neurodegenerative diseases, but these questions must be answered 
for therapeutic success in this area.  
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Hypothesis 
 Pathological tau associates with RNA binding proteins (RBPs) as a core 
feature of its early pathogenesis, leading to the deregulation of RBP physiology. 
 
Specific Aims 
Aim 1: To identify novel associations between RNA binding proteins and pathological tau 
Aim 2: To analyze how the misregulation of RNA binding proteins progresses in 
tauopathies  
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MATERIALS AND METHODS 
Chapter 1 
 
Animal husbandry and tissue collection 
 Animal husbandry for the rTg4510, PS19 and TIA1-/- mice was approved and 
performed as previously described in each indicated reference. For all brain harvesting, 
mice were anesthetized in an isoflurane chamber and perfused with ice cold PBS. Brains 
were then harvested and processed according to each subsequent experiment recorded 
below. 
Human brain samples 
 Temporal cortex tissue from human brain was used for the immunohistochemical 
studies. The samples were de-identified. The cases are listed in Table 2 below: 
Age Gender Braak Stage 
74 M V 
96 M V 
57 F VI 
80 F VI 
97 F V 
87 F VI 
87 F II 
67 F II 
84 F I 
70 M I 
90 F II 
93 F II 
91 M II 
79 M VI 
95 M II 
 
Table 2: Human patients for immunohistochemical study 
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Immunohistochemistry and quantification (Chapter 1) 
 All mouse (n=8 rTg4510 and n=8 wild type C57BL6/J) and human (n=6 AD 
cases and n=5 aged control) tissue was sectioned at 20µm on a cryostat and stained as 
free floating sections using Netwell baskets (VWR Cat#29442-132) in 12 well Falcon 
plates (Cat#353043). Extracted mouse tissues were drop fixed in15mL 4% PFA for 24 
hours, transferred to 15mL 30% sucrose in PBS for 48 hours, then sectioned and stored in 
cryoprotectant (30% ethylene glycol; 30% glycerol; 40% PBS) at -20°C. We note that a 
recent study of stress granule pathology showed excellent labeling of TIA1 and other 
RBPs in a mouse model of tauopathy using perfusion with cold paraformaldehyde (4%), 
followed by drop fixation in cold paraformaldehyde for 2 hrs, transfer to 30% sucrose in 
PBS for at least 48 hrs. Human tissues were fixed and stored in PLP until sectioned using 
a Leica VT1200S vibratome. To quench lipofuscin autofluorescence, sections were 
photobleached under a 1500 lumen white LED bulb for a minimum of 72 hours at 4°C 
while suspended in PBS with no lid or covering. Note that the photobleaching is time-
limited; sections examined were observed to recover lipofuscin autofluorescence after 
approximately 1 week following the photobleaching.  Sections were then washed 3x in 
PBS for 30 seconds each wash followed by a 5-minute incubation in detergent media 
(TBS with 0.25% Triton-X). Human tissue, but not mouse tissue, was then incubated in 
1%w/v sodium borohydride (NaBH4; Sigma-Aldrich Cat#452882-25G) in PBS for 45 
minutes to quench aldehyde autofluorescence which results from the over-fixation of 
tissue. All tissue was then incubated for 1 hour in citrate based antigen unmasking 
solution (Vector Cat#H-3300) at 95°C, with the exception of human TIA1 staining (Fig 
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15C), which was done using 0.05% citraconic anhydride (Sigma-Aldrich Cat#125318-
25G) for 1 hour at 95°C. Tissue was blocked with gentle rotating for 2 hours in detergent 
media with 5% donkey serum (Sigma-Aldrich D9663-10mL) in PBS. After blocking, 
tissue was washed once in PBS for 30 seconds to remove excess detergent, then moved 
into 24 well plates with 200uL of the appropriate primary antibody dilutions and no 
basket overnight at 4°C. To prevent evaporation, the lids of each plate were lined with a 
damp Kimwipe. Antibody catalog numbers and dilutions are recorded in supplementary 
table 2.  
 Following primary antibody incubation, tissue sections were washed 4x in PBS 
using baskets in 12 well plates for 5-minutes each wash. Tissues were then incubated in 
200uL of secondary antibody solution containing a 1:500 dilution of the appropriate 
secondary antibody (Jackson Immunoresearch Alexafluor-488 and 549 secondaries) for 
1.5 hours in the dark at room temperature. If needed, after 1.5 hours 300uL of a 1ug/mL 
DAPI solution was added to each tissue and incubated in the dark for 5 minutes at room 
temperature. Tissues were then washed 4x in PBS for 5 minutes each and carefully 
placed on Millenia 2.0 slides (StatLab Medical Products Cat#318) using a histology 
brush (Fisher Scientific Cat#NC0344756). Excess water was allowed to evaporate for 15 
minutes, then each slide was mounted with 100uL of Prolong Gold Antifade Reagent 
(Thermo Fisher Cat#P36930) and a 1mm cover slip. 
 All imaging was done using a Zeiss LSM 700 confocal microscope at either 40x 
or 63x magnification with a 1AU pinhole. Following imaging, images were processed 
using either Imaris BitPlane software or the Fiji distribution of ImageJ. An Imaris 
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BitPlane surfaces algorithm (Bitplane AG, Zurich, Switzerland) was used to quantify the 
tangle size vs. TIA1 intensity recorded in figure 16. The Coloc2 plugin of Fiji was used 
to determine colocalization parameters recorded in figure 21 following background 
subtraction with a rolling ball radius of 50. Intensity plots for figure 21 were also 
measured and generated using ImageJ-Fiji; regions of interest were set across a line using 
the line tool, and then measured using analyze->plot profile. 
Tau immunoprecipitation for mass spectrometry analysis 
 2.5 month rTg4510 and uninduced transgenic mouse brains (n=4/group) were 
extracted, slowly frozen by submersion in methanol on dry ice, and homogenized in 
RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% 
sodium deoxycholate, pH 6.8) supplemented with protease (Roche Cat#04693159001) 
and phosphatase inhibitor (Roche Cat#04906837001) cocktails. Tau was 
immunoprecipitated from 1 mg cortex lysate using 10 μg of the mouse monoclonal 
Tau13 antibody immobilized on Pierce Direct IP columns according to manufacturer’s 
instructions (Thermo Scientific, Cat#26148). The Tau13 IP eluates were then separated 
on a Novex 4-12%  Bis-Tris polyacrylamide gel (Life Technologies, Cat#NP0323) and 
stained with Simply Blue Coomassie G-250 SafeStain (Life Technologies, Cat#LC6060). 
Whole gel lanes were then excised and shipped to the UMass Mass Spectrometry and 
Proteomics facility for analysis by LC-MS/MS. 
Proteomics, In Gel Digestion:  
Gel slices were cut into 1x1 mm pieces and placed in 1.5ml eppendorf tubes with 
1ml of water for 30 min. The water was removed and 50ul of 250 mM ammonium 
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bicarbonate was added. For reduction 20 μl of a 45 mM solution of 1, 4 dithiothreitol 
(DTT) was added and the samples were incubated at 50 C for 30 min. The samples were 
cooled to room temperature and then for alkylation 20 μl of a 100 mM iodoacetamide 
solution was added and allowed to react for 30 min. The gel slices were washed 2 X with 
1 ml water aliquots. The water was removed and 1ml of 50:50 (50mM Ammonium 
Bicarbonate: Acetonitrile) was placed in each tube and samples were incubated at room 
temperature for 1hr. The solution was then removed and 200 ul of acetonitrile was added 
to each tube at which point the gels slices turned opaque white. The acetonitrile was 
removed and gel slices were further dried in a Speed Vac. Gel slices were rehydrated in 
75 μl of 2ng/μl trypsin (Sigma) in 0.01% ProteaseMAX Surfactant (Promega): 50mM 
Ammonium Bicarbonate. Additional bicarbonate buffer was added to ensure complete 
submersion of the gel slices. Samples were incubated at 37C for 21hrs. The supernatant 
of each sample was then removed and placed in a separate 1.5 ml eppendorf tube. Gel 
slices were further dehydrated with 100 ul of 80:20 (Acetonitrile: 1% formic acid). The 
extract was combined with the supernatants of each sample. The samples were then dried 
down in a Speed Vac. Samples were dissolved in 25 μl of 5% Acetonitrile in 0.1% 
trifluroacetic acid prior to injection on LC/MS/MS. 
LC/MS/MS on Q Exactive:  
A 3.0 μl aliquot was directly injected onto a custom packed 2cm x 100μm C18 
Magic 5μm particle trap column. Labeled peptides were then eluted and sprayed from a 
custom packed emitter (75μm x 25cm C18 Magic 3μm particle) with a linear gradient 
from 95% solvent A (0.1% formic acid in water) to 35% solvent B (0.1% formic acid in 
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Acetonitrile) in 90 minutes at a flow rate of 300 nanoliters per minute on a Waters Nano 
Acquity UPLC system. Data dependent acquisitions were performed on a Q Exactive 
mass spectrometer (Thermo Scientific) according to an experiment where full MS scans 
from 300-1750 m/z were acquired at a resolution of 70,000 followed by 10 MS/MS scans 
acquired under HCD fragmentation at a resolution of 17,500 with an isolation width of 
1.6 Da. Raw data files were processed with 
Proteome Discoverer (version 1.4) prior to searching with Mascot Server (version 
2.5) against the Uniprot database. Search parameters utilized were fully tryptic with 2 
missed cleavages, parent mass tolerances of 10 ppm and fragment mass tolerances of 
0.05 Da. Afixed modification of carbamidomethyl cysteine and variable modifications of 
acetyl (protein N-term), pyro glutamic for N-term glutamine, oxidation of methionine 
were considered. Search results were loaded into the Scaffold Viewer (Proteome 
Software, Inc.). 
Proteomic Analysis:  
Quantitative proteomic analysis was performed using the total ion current (TIC) 
for proteins identified by LC-MS/MS normalized to the TIC level of TIA1 detected in 
each sample. Proteins identified in the TIA1-/- samples were considered to be nonspecific 
binding proteins to the IP antibody and excluded from all subsequent analyses. Gene lists 
of detected proteins were then uploaded into the Database for Annotation, Visualization 
and Integrated Discovery (DAVID) resource available via the NIH website. 
 The proteins identified in the tau binding proteome in WT C57BL/6J cortex 
resulted in 6 clusters with enrichment FDR < 0.05 were identified, and each of the 
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proteins was associated to the cluster(s) based on its membership in the clustered gene 
sets. A network was created by adding a connection between protein pairs sharing 
annotation clusters. Edge weights were determined as the number of shared annotation 
clusters between protein pairs with thicker edges representing stronger functional 
associations between proteins (the smallest number of clusters shared between any two 
proteins was 1, and the largest was 8). The resulting network was visualized using the 
software Gephi 0.8.2 and arranged using the Force Atlas 2 layout algorithm. The network 
was generated using the python programming language (Python Software Foundation), 
and the networkx, numpy, and pandas python packages. 
CoIP Validation of Mass Spectrometry 
 Brains from 6 month old PS19 mice expressing P301S tau were extracted and 
freshly homogenized using 400uL IP lysis buffer (0.025M Tris; 0.15M NaCl; 0.001M 
EDTA; 1% NP-40, 5% glycerol; pH 7.4) supplemented with protease inhibitor cocktail 
(Roche Cat#04693159001), phosphatase inhibitor cocktail (Roche Cat#04906837001), 
and 20units RNase inhibitor (ThermoFisher Scientific #AM2964). 1mg of each lysate 
was pre-cleared with 80uL Protein G Dynabeads, and 50uL of Protein G Dynabeads 
(Invitrogen #10004D) per lysate were prepared with either 10ug Tau13 according to 
manufacturer instructions. Lysates and beads were equivalently pre-cleared and prepared 
with 10ug normal mouse IgG. Pre-cleared lysates were immunoprecipitated with the 
antibody conjugated beads using gentle rotation overnight at 4°C; protein was eluted by 
boiling in Bolt SDS-PAGE sample buffer for 10 minutes and analyzed using SDS-PAGE. 
Antibodies used in the western blot analysis are recorded in supplemental table 2. 
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Sarkosyl fractionation and immunoblotting 
 Extracted brain tissue from (n=3) rTg4510 and (n=3) uninduced Tg4510 control 
mice was weighed and placed in a Beckman centrifuge tube, polycarbonate thick wall 
(Cat#362305). Tissue was homogenized in 4x weight/volume of homogenization buffer 
(50mM Tris; 275mM NaCl; 5mM KCl; 1mM PMSF; pH=8.0 with protease inhibitors, 
phosphatase inhibitors and PMSF added immediately before use) and ultracentrifuged at 
28k rpm (29800g) in a TLA-55 rotor for 20 minutes at 4°C using a Beckman Optima-
TLX 120,000 ultracentrifuge. The supernatant was removed and stored at -80°C as the 
TBS soluble supernatant (supernatant S1); excess supernatant was then vacuumed off the 
pellet, and the pellet was suspended in sucrose buffer (10mM Tris, pH=7.4; 0.8M NaCl; 
10% sucrose; 1mM EGTA; 1mM PMSF). The suspension was ultracentrifuged at 22k 
rpm (26300g) for 20 minutes at 4°C. 450uL of the supernatant was transferred to a new 
tube with the pellet stored at -80°C (pellet P2). This supernatant was incubated with 1% 
Sarkosyl for 5 minutes with gentle rotation at room temperature then 1 hours at 37°C. 
After Sarkosyl incubation the solutions were ultracentrifuged at 55k rpm (150000g) for 1 
hour at 4°C. The supernatant was stored at -80°C (supernatant S3) and the pellet was 
resuspended in 60uL TE buffer (10mM Tris, pH=8.0, 1mM EDTA) and also kept at -
80°C as the P3 pellet. 
 The Sarkosyl soluble S3 supernatant and insoluble P3 pellet were analyzed for 
RBP content using SDS-PAGE and immunoblotting. As the protein concentration of all 
tissues were normalized at the start of fractionation, 20uL of the P3 pellet and 5uL of the 
S3 supernatant were run on a Bolt 4-12% Bis-Tris Plus polyacrylamide gel (Life 
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Technologies Cat#NW04127BOX) at 120V for 1 hour and 15 minutes. Proteins were 
transferred onto nitrocellulose at 12V for 1 hour, and membranes were blocked in Tris-
buffered saline (24g Tris base; 88g NaCl; 1L water; pH = 7.6) with 0.1% Tween (TBS-
T); with 5% non-fat milk for 2 hours. After blocking membranes were incubated with 
10mL of the appropriate primary antibody in TBS-T overnight at 4°C; primary antibodies 
and dilutions are recorded in supplementary table 2. Membranes were washed 4x for 5 
minutes each was in TBS-T, then incubated with the appropriate HRP-conjugated 
secondary antibody at a 1:15,000 dilution in TBS-T (Jackson Immunoresearch)  for 1.5 
hours. Membranes were again washed 4x for 5 minutes each in TBS-T then developed 
using Pierce SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher 
Scientific Cat#34080). Blots were quantified using ImageJ peak analysis. 
Chapter 2 
Fixation optimization of human and mouse tissues 
 For studies to determine optimal fixation methods for brain tissue, mice were 
either drop fixed overnight at 4°C in 4% PFA or perfusion fixed with 4% PFA. For drop 
fixation, n = 4 C57Bl/6 mice were perfused with 10mL ice cold PBS over 5 minutes. 
Brains were extracted and dropped in chilled 4% PFA. After 24 hours, brains were 
transferred to 30% sucrose in PBS with 0.05% sodium azide until sectioned, minimum of 
48 hours. For perfusion fixation, mice were perfused with 10mL of ice cold 4% PFA over 
5 minutes; after extraction, brains were placed directly in 30% sucrose in PBS with 
0.05% sodium azide until sectioned.  
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 To test human tissue, fresh autopsy brain tissue was sliced in 0.5cm2 chunks and 
dropped into cold 4% PFA for either 1, 2, or 24 hours. After the allotted time brains were 
transferred to 30% sucrose in PBS with 0.05% sodium azide until sectioned. This work 
was graciously done by the laboratory of Dr. John Crary at the Mount Sinai Icahn School 
of Medicine. Frozen human tissue chunks were also tested in our lab for fixation with 
both 4% PFA and periodate-lysine-paraformaldehyde (PLP) media. Frozen brain 
specimens were cut into 0.5cm2 chunks, and these chunks were then fixed in PFA or PLP 
for 1, 2, or 8 hours. After fixation chunks were transferred to 30% sucrose in PBS with 
0.05% sodium azide until sectioned. All tissue in this study was sliced by cryostat at 
25um and placed directly onto Millenia 2.0 adhesion slides. Slides were stored at 4°C 
until stained. 
Immunohistochemistry 
 All immunohistochemistry was done on slide mounted tissues; age matched 
tissues from comparison groups (i.e. Wild type and PS19 tau mice) were stained on the 
same slide. Prior to staining, a hydrophobic barrier was drawn around the tissue sections 
using a hydrophobic pen (Vector Labs H-4000). Slides were washed 3x with PBS for 30 
seconds each and blocked for 90 minutes in 7% donkey serum and 0.25% triton-x in 
PBS. After blocking, the primary antibody was diluted in PBS containing 7% donkey 
serum at the following concentrations: AT8, MC1, and PHF1 at 1:300 (Peter Davies); 
TIA1 at 1:100 (Abcam# 140595); HNRNPA0 at 1:300 (Sigma Aldrich #HPA036596); 
DDX5 at 1:200 (Abcam #21696); Lamin B2 at 1:300 (Abcam #151735). Slides were 
incubated with 400uL of the diluted antibody overnight at 4°C while rotating in a 
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humidification chamber (Electron Microscopy Sciences #71397-B). The following day, 
primary antibody was vacuumed off, slides were washed 4x in PBS for 5 minutes a wash, 
and then stained with appropriate secondaries (Alexafluor secondaries, Jackson 
ImmunoResearch Donkey anti-mouse and anti-rabbit at 1:500). The secondaries were 
vacuumed off, the slides were incubated with DAPI at 0.5ug/Ml for 10 minutes, and the 
slides were washed 4x with PBS for five minutes each. Slides were mounted with 100ul 
of prolong gold anti-fade (Thermo Fisher Scientific #P36930) and a 1mm glass coverslip. 
All imaging was performed on a Keyence all-in-one fluorescence microscope BZ-X700.  
 Quantification of nuclear TIA1 was done using ImageJ-Fiji. A region of interest 
was set around the neurons of interest and a nuclear mask was created using auto-
thresholding of the DAPI channel. Nuclei were split (Binary -> Watershed) and nuclear 
TIA1 fluorescence measured using the Analyze Particles command through the TIA1 
channel (red).  
Nuclear Fractionation and Immunoblotting 
 N = 2 C57Bl/6 mice and n = 3 PS19 were perfused with cold PBS as described 
and brains extracted. The hippocampus and frontal cortex was dissected from the fresh 
tissue, weighed, and homogenized in a 10:1 volume:weight of fractionation buffer 
(20mM HEPES pH 7.4, 10mM KCl, 2mM MgCl2, 1mm EDTA, 1mm EGTA; protease 
inhibitor cocktail and 1mM DTT added fresh prior to use) using a teflon pestle and 
motorized rotor in a 1.5mL Eppendorf tube. Homogenates were passed 5 times through a 
27 gauge needle using 1 mL syringe, incubated on ice for 20 minutes, and spun at 1000g 
at 4°C for 10 minutes. The supernatant was collected as the cytoplasmic fraction; the 
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nuclear pellet was washed once in 500uL cold fractionation buffer and passed through a 
25 gauge needle 5 times using a 1mL syringe. Nuclei were pelleted at 3,000g for 10 
minutes at 4°C and resuspended in 2:1 volume:tissue-weight of PBS with 0.1% SDS. The 
suspension was sonicated for 5s at low power to shear DNA and remaining nuclei. This 
was then spun at 8,000g to clear remaining debris and the supernatant was kept as the 
nuclear fraction. Both fractions were immunoblotted for TIA1 (Proteintech #12133-2-
AP), HNRNPA0 (Sigma Aldrich #HPA036596), DDX5 (Abcam #21696) and Histone H1 
(Proteintech #17510-1-AP) all at 1:1000 in TBS-0.1% tween as described and quantified 
using ImageJ lane analysis. 
AAV Injections and Stable Expression of miRFP-TIA1 
 P0 pups from PS19 litters were injected with 2ul of AAV9-miRFP::TIA1 per 
ventricle using a Hamilton syringe. At four months of age, littermates were sacrificed, 
perfused with 4% PFA according to our protocol, and brains were sectioned onto slides at 
25um. Brains were imaged for far-red fluorescence, and stained according the 
immunohistochemistry protocol detailed above.  
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CHAPTER ONE 
RNA binding proteins colocalize with small tau inclusions in tauopathy 
 
Published as Maziuk et al. Acta Neuropathological Communications (2018), with minor  
 
edits 
 
 
Introduction 
RNA binding proteins (RBPs) have emerged as major factors in a number of 
neurodegenerative disorders, including tauopathies (B. Maziuk, Ballance, & Wolozin, 
2017). RBPs represent a large class of proteins responsible for RNA metabolism, 
regulating key events including mRNA maturation, trafficking, and eventual translation. 
Importantly, many RBPs have been shown to have strong genetic links to 
neurodegenerative disease; for example, mutations in TDP-43, FUS, hnRNPA1, and 
ATXN2 have all been shown to cause amyotrophic lateral sclerosis (ALS), frontotemporal 
lobar degeneration (FTLD) and/or spinocerebellar ataxia. Other RBPs have also been 
implicated in AD, Huntington’s disease, and Creutzfeldt-Jakob disease. 
Following these initial discoveries, evidence now suggests that transient 
aggregation mediated by low-complexity domains within RBPs is crucial for the 
involvement of these proteins in disease. RBPs typically contain a “prion-like”, low 
complexity glycine-rich domain in their sequences, which regulate their self-aggregation 
(Couthouis et al., 2011). This regulated aggregation is important for RBP function, as many 
RBPs regulate the formation of a variety of ribonucleoprotein (RNP) granules. Such 
granules, which include stress granules (SGs) and P-bodies, are responsible for the 
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transient recruitment and aggregation of mRNA transcripts for varying purposes (Anderson 
& Kedersha, 2006) (Buchan & Parker, 2009). SGs recruit mRNA into granules for storage 
and protection following translational stress, while P-bodies recruit mRNA for eventual 
degradation. Many disease-linked RBPs are proteins involved in the formation and 
maintenance of SGs. 
In particular, recent findings have shown that T-cell intracellular antigen 1 (TIA1) 
and other RBPs interact with hyper-phosphorylated tau and accumulate in tandem with tau 
pathology in diseases such as Alzheimer’s disease (AD) and frontotemporal dementia 
(FTD) (Vanderweyde et al., 2012) (Vanderweyde et al., 2016). RBPs also regulate splicing 
of MAPT exon 10, which provides an additional mechanism for control of tau aggregation 
by determining whether the tau transcript codes for 3 or 4 microtubule repeats (Y. Wang 
& Mandelkow, 2016). The aggregation of tau is a major pathological hallmark of these 
diseases, where the microtubule associated protein tau becomes hyperphosphorylated, and 
mislocalizes in the soma (Ballatore et al., 2007). Once in the soma, tau begins to aggregate, 
eventually forming large neurofibrillary tangles and resulting in neurodegeneration. 
Recently, our lab demonstrated that tau interacts with TIA1 in SGs, which increases in 
sarkosyl insoluble aggregates. The association of tau with TIA1 and SGs also was shown 
to promote tau-mediated degeneration of primary hippocampal neurons (Vanderweyde et 
al., 2016). This phenotype can be rescued by TIA1 knockdown in primary neurons, and we 
proceeded to show that TIA1 reduction (haploinsufficiency) is also protective in vivo, 
reducing neurodegeneration, rescuing cognition and increasing survival in the PS19 mouse 
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model of tauopathy (Apicco et al., 2017). These results point to an essential role for TIA1 
and SG biology in the pathophysiology of tauopathy.  
We now present an enhanced view of the interaction of RBPs in the 
pathophysiology of tauopathy. We have used a proteomic approach to identify multiple 
RBPs that have significantly altered associations with tau as pathology develops in the 
rTg4510 mouse model of tauopathy including multiple splicing factors. rTg4510 mouse 
model of tauopathy inducibly expresses P301L 4R0N tau under control of a tetracycline 
promoter, and when grown absent doxycycline develop pathology by 4-5 months 
(Santacruz et al., 2005). We also present optimized immunohistochemical methods for 
detecting RBPs in pathological tissues. We combine the optimized immunohistochemical 
methods with biochemical methods to validate the proteomic findings. We identify specific 
RBPs that associate with pathological phospho-tau early in disease and become 
increasingly insoluble as disease progresses. Together our results provide important 
evidence indicating that RNA binding protein pathologies are a major feature of tauopathy 
Results 
TIA1 colocalizes with phosphorylated tau in tauopathy 
Recent work from our laboratory demonstrates that TIA1 and other SG markers 
colocalize with pathological tau in Tg4510 and PS19 mouse brains as well as human 
post-mortem AD and FTDP-17 brain samples (Vanderweyde et al., 2012). 
Immunohistochemical identification of TIA1 inclusions in pathological samples has 
proven to be particularly difficult, with some observing TIA1 inclusions, and others 
unable to observe inclusions (Fujita et al., 2008) (Mackenzie et al., 2018). While this 
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could represent differences in the types of cases examined, we have also observed TIA1 
reactivity to be highly sensitive to methodological conditions.  
To improve reproducibility among laboratories, we set out to define optimal 
conditions for TIA1 immunohistochemistry. We began by determining optimal 
conditions for fixation of mouse tissue. rTg4510 tissues were drop-fixed in 4% buffered 
paraformaldehyde for 24 or 48 hours, then transferred to 30% sucrose, incubated at 4° C 
for 48 hrs, sectioned and subjected to immunohistochemistry. Shorter fixation times 
produced much stronger reactivity for both TIA1 and NeuN, which is also an RNA 
binding protein (Fig. 12).  The 24 hr fixation protocol was used for all subsequent 
experiments using animal tissues. We also optimized conditions to reduce background. 
Our previous studies used Sudan black to quench background fluorescence, however such 
quenching also has the drawback of reducing antibody signals (Vanderweyde et al., 
2012). Photobleaching proved to provide much more effective quenching of 
autofluorescence without significant loss of antibody reactivity (Fig. 13). Application of 
shorter fixation times and photobleaching significantly improved the sensitivity for 
detecting RBPs in tissue samples. 
Next we compared commercially available antibodies for immunohistochemical 
reactivity. We observed that the anti-TIA1 antibody from Abcam (Abcam cat#40693) 
gave the strongest results, thought the lot of antibody could impact results (Fig. 14A). 
Using the Abcam antibody, we consistently observed TIA1 colocalization with CP13 
positive phospho-tau in the rTg4510, the PS19 mouse models of tauopathy, and human 
AD tissue (Fig. 15A-C). The strength of reactivity varied with lot number, and thus the  
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Figure 12: Duration of fixation affects sensitivity of RBP detection 
Samples were fixed for 24 (top row) or 48 hrs (bottom row) with 4% PFA (equivalent to 10% formalin), 
with NeuN or TIA1 imaged by immunofluorescence; DAPI was used to identify nuclei. 
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Figure 13: Photobleaching of tissue removes autofluorescence from lipofuscin and the 
extracellular matrix. 
Human AD tissue was treated with white light from an LED bulb for 72 hours and then imaged for 
background fluorescence. While untreated tissue shows significant autofluoresence in the red and green 
channels (top), this fluorescence was removed with photobleaching (bottom).  
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Figure 14: TIA1 antibodies demonstrate significant variability 
Four commercial TIA1 antibodies were screened for performance in fluorescent immunohistochemical 
assays: Abcam 40693 (A), Santa Cruz 1751 (B), Abcam 140595 (C), and Cell Signaling 1398S (D). Of 
these, only Abcam 40693 demonstrated affinity for both cytoplasmic and nuclear TIA1 with minimal 
background reactivity. However, this antibody also shows significant performance variability between lots 
(E). 
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Figure 15: TIA1 colocalizes with phosphorylated tau. 
Immunohistochemical analysis of the stress granule nucleating protein TIA1 (red) shows colocalization 
with phosphorylated tau (CP13 antibody against pSer202, green) in rTg4510 (A), PS19 (B) and human AD 
tissues (C) with DAPI in blue. D) Immunohistochemistry of TIA1 on rTg4510 with and without 
immunosorbtion using TIA1 peptide, as well as TIA1 staining of TIA1 knockout mouse tissue, also show 
that the TIA1 antibody used for this analysis is specific for TIA1 and does not have off-target staining.  
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work in this manuscript used lot GR151575 (Fig. 14B). Reactivity with antibodies from 
other vendors did not work as well as the Abcam antibodies (Fig 14). In all cases, 
specificity of the TIA1 reactivity was demonstrated by the absence of anti-TIA1 
reactivity observed following immuno-adsorption or staining of TIA1 knockout brain 
tissue (Fig. 15D). These results demonstrate that immunohistochemical reactivity with 
the Abcam anti-TIA1 antibody is bona-fide TIA1 reactivity. 
 We proceeded to characterize how the co-localization of TIA1 and tau varied with 
the type of tau pathology. Analysis of patterns of co-localization in 6 month-old rTg4510 
brain tissue demonstrated a distinct correlation of TIA1 co-localization with the size of 
CP13-positive tau inclusions (Fig. 16). Abundant co-localization was observed with small 
CP13 reactive puncta, while little co-localization was observed with large fibrillar CP13 
positive tau inclusions. Previous results from our laboratory indicate that TIA1 
selectively interacts with oligomeric tau (Apicco et al., 2017). To test whether the small 
TIA1 reactive inclusions contained tau oligomers, we probed the tissues with the anti-tau 
oligomer antibody TOC1 (Kanaan et al., 2013). Strong co-localization was observed 
between anti-TIA1 and the TOC1 tau oligomer specific antibodies (Fig. 17, R = -0.1617, 
p=0.0404). From this we conclude that TIA1 preferentially associates with small tau 
inclusions containing oligomeric tau. 
Other RNA Binding proteins change in their association to tau in tauopathy 
The association of phosphorylated tau with the stress granule protein TIA1 raises 
the possibility that other RBPs and ribosomal proteins might also interact with tau 
(Meier, Bell, Lyons, Ingram, et al., 2016)  
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Figure 16: TIA1 preferentially colocalizes with pathological tau not in mature tangles. 
Analysis of TIA1-tau colocalization in rTg4510 tissues indicates that TIA1 primarily has cytoplasmic 
colocalization with smaller tau aggregates (white arrow) over larger NFT-like tau aggregates (pink arrow). 
This is quantified using Imaris Bitplane software, where cytoplasmic TIA1 intensity negatively correlates 
with the size of tau tangles in neurons (R = -0.1617 with a two tailed p value of 0.0404). 
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Figure 17: TIA1 colocalizes with oligomeric tau in rTg4510 mouse brain. 
Co-labeling of rTg4510 mouse brain with TIA1 (red) and TOC1, an antibody specific for oligomeric tau 
(green) shows colocalization between the two proteins. 
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(Meier, Bell, Lyons, Rodriguez-Rivera, et al., 2016). To explore the tau interactome, we 
immunoprecipitated (IP) total human tau from 2.5 month old Tg4510 mouse frontal 
cortex expressing low or high amounts of human tau protein due to inclusion or exclusion 
of doxycycline from the mouse chow, respectively; the human specific Tau13 antibody 
was used for the IPs were performed using the antibody Tau13, which is a high affinity 
antibody that selectively recognizes total human tau (independent of tau phosphorylation 
state) (Combs & Kanaan, 2017). We also did IPs from MAPT -/- mice to provide 
negative controls for the IPs. This design allowed exploration of neurons exposed to 
relatively low or high amounts of stress, but preceding a phase with extensive 
neurodegeneration.  The tau complexes were then analyzed using orbitrap mass 
spectrometry to identify proteins in the tau interactome; any proteins pulled down by the 
Tau13 antibody from the MAPT-/- mice were removed from tau interactome observed in 
the rTg4510 IPs. This analysis identified a large number of proteins associated with tau, 
including RBPs, translational and ribosomal proteins, cytoskeletal proteins, chaperones, 
heat shock proteins and synaptic proteins (Fig. 18B) (Appendix 1).  
Comparing the tau networks from the induced and un-induced rTg4510 mice 
revealed striking changes. Multiple proteins also showed decreased association with tau 
in the 2.5 m induced rTg4510 mice. Proteins linked to RNA metabolism comprised 3 of 
the top 6 GO annotations categories of decreased proteins (Fig. 18A, bottom panel). 
Interaction of tau with some of these proteins, including HNRNPA0, HNRNPK, eIF4a, 
and RPL11, was cross-validated by immunoprecipitating tau from 6 month old PS19 
P301S tau mouse brains; these mice overexpress mutant P301S tau at 5 times endogenous   
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Figure 18: RNA binding proteins change in their association to tau in tauopathy 
Using Tau13 antibody, tau was immunoprecipitated from the cortex of either 2.5 month old induced or 
uninduced rTg4510 brains.The co-immunoprecipitating proteins were subsequently identified by mass 
spectrometry. A variety of nucleotide binding and ribonucleoproteins show differential association to tau in 
rTg4510 tissue compared to WT tissue  as indicated by significantly upregulated and downregulated 
annotation terms (A). Part (B) represents a network diagram of proteins enriched in the tau interactome. 
Red nodes denote proteins whose association with tau is ≥ 5-fold increased in Tg4510 vs uninduced 
control. Blue nodes denote proteins whose association with tau is ≥ 5-fold decreased in Tg4510 vs control. 
Node size is proportional to degree of replication (N=4), non-replicating proteins excluded. Key proteins 
include EWSR1, HNRNPA0, PABP, PCBP2, DDX5, TAF15, FMR1, RPL and RPS family members, and 
eIF4a2. 
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levels (Fig. 19). Confirmation is also provided by comparison to our prior study showing 
the requirement of tau for the presence of many proteins in the TIA1 interactome network 
(Vanderweyde et al., 2016).  These changes corresponded to large-scale changes in the 
interaction of tau with these particular groups of proteins. For instance, 65% of proteins 
in the RBP group showed decreased association with disease; in contrast, only 16% of 
proteins in the synaptic and vesicular protein group showed decreased association with 
disease.  
The groups of proteins whose interaction of tau increased with disease were 
equally striking. Heat shock proteins/chaperones and phospho-proteins were 2 of the 3 
groups of proteins upregulated in the 2.5 m induced rTg4510 mouse cortex (Fig.18A, top 
panel), with 37% of heat shock or chaperone proteins showing increased association with 
tau with disease. This upregulation is consistent with the stress associated with pre-tangle 
stage that predominates in the 2.5 m rTg4510 mouse (Santacruz et al., 2005). 
Interestingly, the third group of proteins whose association with tau increased in the 2.5 
m mice was nucleotide binding proteins, which includes RBPs such as EWSR1, TAF15 
and HNRNPA0, which we previously reported to co-localize with tau pathology in the 
rTg4510 model of tauopathy (Vanderweyde et al., 2016). In addition, aggregation-
enhancing mutations in EWSR1 and TAF15 are associated with ALS, suggesting that 
changes in the biology of these proteins are sufficient to drive neurodegenerative disease 
(Couthouis et al., 2011). Taken together, these results highlight that complexes 
containing tau and RBPs are a major feature of the pathophysiology of tauopathy. 
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Figure 19: Binding of tau to RNA binding proteins is validated by immunoblot. 
Human mutant tau was immunoprecipitated from P301S overexpressing mice using the tau13 antibody 
(left) and compared to an IgG negative control (right). Multiple proteins including HNRNPA0, HNRNPK, 
eIF4a2, and RPL11 were identified to co-precipitate with tau as validation of the mass spectrometry in 
Figure 18. 
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RNA binding proteins become insoluble in tauopathy 
 A key feature of RBP biology is the formation of transient, dynamic complexes, 
such as stress granules, P-bodies, transport granules, and even splicing complexes. With 
time or in disease, many RBPs exhibit a tendency to develop into insoluble aggregates. 
To explore whether RBPs become insoluble in mouse models of tauopathy, we 
fractionated frontal cortex from 8m old rTg4510 mice aged with low or high levels of 
human tau (i.e., ± dox). The samples were then biochemically separated into sarkosyl 
soluble or insoluble fractions and immunoblotted.  Levels of RBPs in the sarkosyl soluble 
(S3) group did not change with disease state (Fig. 20). In contrast, the amount of RBP 
present in the insoluble (P3) fraction was elevated in diseased tissues for most of the 
RBPs examined (Fig. 20). Analysis of TDP-43 levels showed no change with disease 
state, consistent with the lack of association of this protein with tau aggregation 
processes. These results suggest that a range of RBPs form insoluble aggregates with 
disease in tauopathy. 
RNA binding proteins colocalize with phospho-tau but not mature neurofibrillary tangles 
in tauopathy 
 Using immunohistochemistry with confocal microscopy, we proceeded to 
examine how deposition of RBPs in disease correlated with tau pathology.  We examined  
proteins identified by mass spectrometry in the tau network (Fig. 18), proteins that we 
had previously shown to associate with tau, as well as proteins thought to be involved in 
the RNA translational stress response and stress granule formation. Frontal cortex from 6 
month old rTg4510 mice was used for the study because of the presence of both mature  
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Figure 20: RNA binding proteins become insoluble in the cortex of rTg4510 mice. 
Immunoblots of the sarkosyl soluble (S3) and insoluble (P3) fractions isolated from rTg4510 cortical 
tissues indicate that many RBPs become insoluble as tau pathology develops. The fractions were also 
probed for TDP-43, which is not associated with tau aggregation. Quantification of these immunoblots 
(C,D) shows statistically significant RBP accumulation in the P3 fraction of induced rTg4510 mouse cortex 
using a two-tailed t-test (p = 0.00599 for TAOK1; p = 0.0007599 for EWSR1; p = 0.0122 for TAF15; p = 
0.000252 for RPL7; p = 0.00195 for PABP; p = 0.0926 for DDX5; p = 0.0638 for HNRNPA0). 
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and evolving tau pathology at this age.  Imaging of RBPs using fluorescence 
immunohistochemistry showed the accumulation of RBPs co-localized with or near 
diffuse deposits of phosphorylated tau identified with CP13, an antibody recognizing 
pS202 (Fig. 21A). The RBPs and proteins linked to RNA metabolism primarily 
colocalized with phosphorylated tau present in neuronal somas; scatterplots done on the 
images demonstrated that when overlap was present there was strong co-localization with 
tau pathology (Fig. 21E). We quantified the fraction of neurons exhibiting CP13 
reactivity that also exhibited RBP reactivity (Fig. 21F). Robust correlation for CP13/RBP 
co-localization was observed for DDX6, eIF2, hnRNPA0 and PABP, but not for U2AF2 
(Fig. 21E); robust correlation was also observed for TIA1 (Fig. 15). Interestingly, little 
colocalization was observed with mature NFTs showing bright condensed CP13 
reactivity (Fig. 21B), consistent with the studies of TIA1 in figure 16. Some of the RBPs 
(e.g., DDX6 and hnRNPA0) appear to remain as aggregates but accumulate adjacent to 
the tau NFTs, as if the RBPs are excluded from large, consolidated tau tangles, and 
pushed to the periphery of such tangles (Fig. 21B).  
 Finally, we examined the pattern of reactivity of RBPs in human tissue. We 
examined temporal cortex of late Braak stage V and VI human AD patients (Fig. 22). At 
this stage of disease, CP13 positive phospho-tau exists predominantly as NFTs  (showing  
bright condensed CP13 reactivity), with little diffuse phospho-tau, such as is seen at 6-8 
months of age in the rTg4510 mouse model (Fig. 22). RBP inclusions were readily 
apparent in the human tissues using antibodies against DDX6 and hnRNPA0 (Fig. 23). 
Comparison of the distribution of the RBP and tau deposits in individual neurons  
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Figure 21: RNA binding proteins show significant colocalization with diffuse phospho-tau 
but not NFTs in the rTg4510 cortex. 
 (A) Immunohistochemical analysis of rTg4510 tissue (n=3) has also revealed a significant colocalization 
in the cortex between the RBPs DDX6, PABP, HNRNPA0, and eIF2a (red) with pathological phospho-tau 
stained using the CP13 antibody (green). However, the RBP and splicing factor U2AF2 does not show 
significant correlation. To the right of each merged image is a scatterplot of the pixel intensities for each 
pixel of the image in the red channel vs. the green (Pearson correlation coefficients r = 0.773 for DDX6, 
0.791 for eIF2α, 0.325 for HNRNPA0, 0.798 for PABP, and -0.14 for U2AF2).  This colocalization is 
greatly reduced and/or completely lost as tau aggregates into large NFTs which are brightly fluorescent and 
fill the cell bodies of neurons (B) (r = 0.069 for DDX6, 0.372 for eIF2α, 0.481 for PABP, -0.03 for 
HNRNPA0, and -0.009 for U2AF2).  (C) HNRNPA0 is predominantly nuclear in healthy animals, while 
the rTg4510 staining shows significant cytoplasmic localization of HNRNPA0 (A,B). (D) Negative 
controls IHC using rabbit and mouse normal IgG indicates that there is no off target staining or 
fluorescence in our tissues. (E) Pearson coefficients of correlation between CP13 positive tau with RBPs 
DDX6, eIF2α, HNRNPA0, PABP, and U2AF2 are graphed for individual neurons using ImageJ. For all 
cases except U2AF2, neurons show heterogeneity in colocalization between phospho-tau and the RBPs 
stained, from no colocalization to fully overlapping reactivity patterns in individual neurons. The percent of 
neurons with r > 0.3 is graphed in (F) as the percentage of neurons showing moderate to strong correlations 
between green:red intensity (DDX6 = 36% of neurons; eIF2α = 54% of neurons; HNRNPA0 = 35% of 
neurons; PABP = 33% of neurons; U2AF2 = 0% of neurons).  
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suggests an inverse correlation between RBP localization and mature NFTs similar to that 
observed in the rTg4510 mouse tissue (Fig. 23). In addition, we observed that some RBPs 
(e.g., DDX6 and hnRNP0) accumulated as pathological inclusions, but accumulated 
adjacent to the mature tangles, much like what was observed in rTg4510 mice (Fig. 23). 
These results demonstrate that deposits of RBPs occur near deposits of pathological tau, 
but suggest that RBPs are excluded from the aggregated tau as the deposits consolidate. 
 
 
Figure 22: Consolidated but not diffuse phospho-tau is present in late stage human AD 
tissue. 
6 month rTg4510 mouse tissue (left) and human AD tissue (right) were compared using 
immunohistochemistry for tangle morphology and intensity. In the human tissue, CP13 positive tau exists 
entirely as fluorescently bright NFTs which extend into the processes. In contrast, the mouse tissue shows a 
continuum of pathological tau ranging from less intense, diffuse phospho-tau in the soma (white arrows) to 
higher intensity NFT formations as well as small CP13 positive puncta. 
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Figure 23: RBPs show granularization and interfacing with NFTs in late stage human AD 
tissue. 
Immunohistochemical analysis of human AD frontal cortex tissue (n=6) shows that RBPs (red) and NFTs 
stained with CP13 tau (green) do not colocalize (r = 0.001 for DDX6; 0.176 for eIF2α; 0.031 for 
HNRNPA0; and 0.222 for PABP). However, trace analyses across lines within the image (yellow bars) 
indicate that peak fluorescent intensities (reported as fluorescence intensity plots over the distance of the 
line for tau in green and the RBP in red) between phospho-tau and multiple RBPs are immediately adjacent 
to each other, indicating protein interfacing or interaction between the edges of NFTs and RBPs. 
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Discussion 
Characterization of the tau interactome in the rTg4510 mouse model of tauopathy 
reveals striking disease-related changes in interactions between tau and multiple RBPs. 
About 65% of proteins in the RBP group show decreased tau association with disease. A 
smaller number of RBPs increase the association of tau with disease, including EWSR1, 
TAF15 and hnRNPA0, each of which have been linked to ALS (e.g., EWSR1 or TAF15) 
or have related family members linked to ALS (hnRNPA0 shares homology with 
hnRNPA2B1). Formation of aggregates was evident biochemically and by 
immuhistochemisty which is consistent with prior studies showing multiple U1 
spliceosome components that accumulate in the sarkosyl-insoluble fraction of AD tissue 
(Bai et al., 2013). 
Imaging studies suggest that the pattern of co-localization varied depending on 
the type of RBP, and the size of the inclusion.  For the RBPs examined in this 
manuscript, TIA1 showed the strongest co-localization with tau pathology. Co-
localization for TIA1 with tau could be observed for phospho-tau (CP12, p-S202) and 
oligomeric tau (TOC1).  Other RBPs, including hnRNPA0, DDX6, eIF2 and (to a lesser 
extent) PABP also co-localized with phospho-tau pathology.  Direct co-localization was 
observed with small tau puncta, but for large tau inclusions these RBPs tended to 
accumulate immediately adjacent to the inclusion. The observation of RBP inclusions 
adjacent to tau tangles has also been observed for small nuclear ribonuclear proteins, such 
as U2AF2 (Hales et al., 2014). The differential localization of RBP inclusion with tau 
aggregate size suggests a model in which these proteins initially co-localize with tau but 
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become excluded as the tau aggregates consolidate into mature neurofibrillary tangles. 
This work adds key information to our prior data indicating that phospho-tau 
(specifically, tau phosphorylated at the classic proline directed serine/threonine sites 
associated with pathology) promotes SG formation (Vanderweyde et al., 2016).  
These results suggest the hypothesis that tau and RBPs exhibit progressive 
maturation. This process appears to begin with a stress response that includes the 
translational stress response, which leads to cytoplasmic translocation of nuclear RBPs, 
followed by formation of functional SGs in part through interaction with phosphorylated, 
oligomeric tau (Apicco et al., 2017). The association of tau with SGs also produces 
aggregation, much as occurs with disease-prone RBPs during extended or repetitive 
periods of liquid-liquid phase separation (LLPS) (Hyman, Weber, & Jülicher, 2014) (Lin 
et al., 2015). Tau also undergoes LLPS, and does so in a manner that is accelerated by the 
presence of mRNA (X. Zhang et al., 2017). The similar biophysical behavior of tau and 
RBPs, the association of tau with SGs, the ability of tau to promote SG formation, and 
the tendency of tau to aggregate in the presence of SGs, provide a strong basis for a 
model based on the interaction of tau with SGs. Co-localization of tau with SG-associated 
RBPs suggest that the tau complexes with RBPs complexes that either are SGs or 
resemble SGs, which then mature during chronic stress into persistent pathological SGs 
(Fig. 24). Based on our data, we hypothesize that persistent SGs lose many types of RBPs 
and perhaps reducing their physiological activity; ubiquitin is added into the model at this 
point to reflect the well-documented association of ubiquitin with mature tangle 
pathology (Y. Zhang, Chen, Zhao, Ponnusamy, & Liu, 2017). As the aggregated tau in 
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these pathological SGs consolidates they appear to exclude many RBPs, and ultimate 
become the inert pathological structures that are referred to as neurofibrillary tangles. 
Meanwhile, the excluded RBPs form inclusions that accumulate adjacent to the 
neurofibrillary tangles. The latter stages of this hypothesis remain to be explicitly tested 
beyond the correlative evidence presented above, but the model sets up a paradigm to 
guide future studies. 
This model is further supported by accumulating evidence pointing to a persistent 
translational stress response as a key pathway leading to the accumulation of SGs. 
Chronic disease could produce a chronic stress, which leads to persistence of SGs. The 
high concentration of RBPs in SGs (100 – 400-fold higher than dispersed RBP levels) 
creates conditions that also promote aggregation of RBPs into insoluble amyloids, which 
over time accumulate (Shin & Brangwynne, 2017). Support for the persistent SG 
hypothesis comes from protection experiments in cell culture and in transgenic models. 
Bonini and colleagues demonstrated that chemical inhibition of the SG pathway rescues 
the ALS phenotype in drosophila (Kim et al., 2014). Ataxin-2 deletion, which also 
inhibits the SG/translational stress response pathway, also delayed disease progression in 
a mouse model of ALS (Becker et al., 2017).  The relevance of the SG pathway to 
tauopathy was recently demonstrated by our observation that TIA1 reduction protects 
against disease progression in a mouse model of tauopathy (Apicco et al., 2017).  Studies 
using primary neurons support these results by demonstrating that both RNAi knockdown 
of TIA1 and chemical inhibition of the SG pathway are able to prevent tau-mediated 
toxicity (Vanderweyde et al., 2016). Thus, multiple independent lines of evidence 
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demonstrate that RBPs, SGs and the translational stress response contribute to the 
pathophysiology of tauopathy and other neurodegenerative diseases. 
 
Figure 24: Model for the evolution of tau pathology. 
A) Stress elicits translocation of nuclear RBPs, such as TIA1 and HNRNPA0, to the cytoplasm where they 
distribute diffusely in the cytoplasm.  B) Core nucleating RBPs, such as TIA1, coalesce to form SGs, in a 
process that is stimulated by tau oligomers. Secondary nucleation brings in other RBPs, such as EWSR1, 
PABP, DDX6, EIFs, etc. C) Persistent stress (such as occurs in disease) causes particularly insoluble RBPs 
(and tau) to consolidate to form persistent pathological stress granules. More soluble RBPs separate from 
the persistent pathological SG, and disperse without aggregating. D) The tau oligomers evolve into fibrils 
forming pathological puncta, which contain classic markers of pathology such as hyper-phosphorylation 
and ubiquitination [43]. Other RBPs that remain associated with the persistent pathological SG, begin to 
form aggregated puncta around the tau puncta. E) Tau fibrillizes forming neurofibrillary tangles, which are 
relatively inert, do not act in the translational stress response and contain few RBSs. 
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The putative role for tau in regulating the RNA metabolism is supported by 
proteomic studies of tau interactomes from multiple different groups, which also identify 
similar classes of proteins that associate with tau. Immunoprecipitation and mass 
spectrometry of tau (both WT and P301L) binding proteins from SH-SY5Y 
neuroblastoma cells showed strong overlap of RBPs and ribosomal protein with the 
proteins identified in our study, including EWSR1, DDX5 & 17, hnRNPK, L, R and U, 
as well as ribosomal proteins RPL7, 8, 27 and 30 (Gunawardana et al., 2015). Proteomic 
studies of complexes containing tau from the rTg4510 mouse model and human AD 
tissues also report RNA binding and nucleotide binding proteins in their results, as well 
as multiple heat shock proteins and chaperones (Begcevic et al., 2013); work from the 
Abisambra laboratory also directly demonstrates that tau over-expression inhibits RNA 
translation (Koren et al., 2019). Studies using HeLa cells report multiple RBPs in the tau 
interactome, including TIA1, hnRNP family members, and many ribosomal subunit 
proteins, and also demonstrated the presence of aggregated RBPs in the AD brain 
(Thompson et al., 2012). A recent study of tau-associated proteins in lymphoblastoid cell 
lines containing AKAP9 mutations linked to AD show enrichment of RNA binding and 
splicosemal proteins in the tau proteome (Ikezu et al., 2018). These proteins again include 
EWSR1, TAF15, DDX family members, and RPL family members, which parallels our 
findings.  Finally, our own work previously demonstrated the association of TIA1 with 
tau by both proteomic analysis as well as immunoprecipitation (Vanderweyde et al., 
2016).  These data demonstrate that identification of complexes containing tau and RBPs 
is a reproducible observation. The nature of the tau species responsible for binding to 
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each RBP remains to be determined, and might differ between tau monomers, oligomers 
and fibrils; for instance, our recent study suggest that TIA1 exhibits preference for tau 
oligomers (Apicco et al., 2017). The studies also provide strong support for an emerging 
consensus that tau functions in stress to regulate the translation stress response through 
interaction with RBPs and SGs. 
Our current study combines with accumulating prior studies to suggest that 
tauopathies (including AD) exist in the spectrum of neurodegenerative diseases and 
myopathies that are associated with dysfunction of RBPs, which already includes ALS 
and FTD. The current work advances the field by identifying a number of RBPs that can 
be reliably associated by immunohistochemistry with tau pathology, and providing 
optimized methods for detecting the association. These advances will facilitate rigor and 
reproducibility for this emerging field. Finally, the consistent role of RBPs and SGs in the 
mechanisms of multiple neurodegenerative diseases suggests that dysfunction of RBPs, 
SGs and translational stress response pathways plays a fundamental role in the 
pathophysiology of neurodegenerative diseases, and that seemingly disparate diseases 
might converge on common downstream mechanisms for neurodegeneration. 
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CHAPTER TWO 
Deregulation of nuclear RNA binding proteins precedes tau tangle formation  
 
and drives phospho-tau accumulation in vivo 
 
 
Introduction 
 The aggregation of the microtubule associated protein tau (MAPT) is a core 
feature of many forms of dementia collectively termed tauopathies; these diseases include 
Alzheimer’s disease (AD), chronic traumatic encephalopathy (CTE), progressive 
supranuclear palsy (PSP), frontotemporal dementia and parkinsonism linked to 
chromosome 17 (FTDP-17), and corticobasal degeneration (CBD), among others 
(Ballatore et al., 2007). Despite major ongoing efforts, definitive cellular mechanisms 
underlying tau aggregation as well as resultant neurotoxicity have not been conclusively 
proven. However, recent studies have indicated that RNA binding proteins (RPBs) may 
be a vital element in tau aggregation and toxicity (Vanderweyde et al., 2012; 
Vanderweyde et al., 2016; Apicco et al., 2017; Maziuk et al., 2018; Jiang et al., 2019). 
 RBPs are a large class of protein responsible for regulating key events in RNA 
metabolism including transcription, splicing, maturation, trafficking, and translation 
(Hentze, Castello, Schwarzl, & Preiss, 2018). Many of these proteins also have 
established genetic links to other neurodegenerative diseases; this includes TAR DNA-
binding protein 43 (TDP-43), fused in sarcoma (FUS), and ataxin 2 (ATXN2) in 
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) 
(Maziuk et al., 2017). These proteins typically undergo transient aggregation as a normal 
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part of their biology, and this propensity to aggregate is crucial in understanding their 
neurodegenerative effects. Many RBPs contain a “prion-like”, glycine rich low 
complexity domain which regulates their self-aggregation (Couthouis et al., 2011) (Gitler 
& Shorter, 2011). Normally this self-aggregation serves as the basis for ribonucleoprotein 
(RNP) granule formation such as stress granules (SGs) or P-bodies. In disease, persistent 
self-aggregation may instead lead to RBP fibrillization and the formation of more stable, 
insoluble, potentially toxic aggregates. 
 Recent studies have shown that T-cell intracellular antigen 1 (TIA1) and other 
RBPs associate with pathological tau in a variety of experimental systems. TIA1 and tau 
synergistically promote the formation of insoluble SGs and tau aggregates in vitro, the 
association of these two proteins promotes tau mediated degeneration of primary 
hippocampal neurons, and reduction of TIA1 in a mouse model of tauopathy protects 
against tau mediated neurodegeneration (Vanderweyde et al., 2016) (Apicco et al., 2017). 
Further experiments have also shown that TIA1 is required for the propagation of toxic 
oligomeric tau species and their neurotoxicity (Jiang et al., 2019). These results indicate 
that TIA1 is a significant part of tau pathophysiology, though the direct mechanism 
underlying TIA1-tau association and the resulting toxicity remains unknown.  
 Other RBPs including eukaryotic initiation factors (eIFs), ribosomal family 
members, heterogeneous ribonucleoprotein (HNRNP) family members, and dead-box 
helicase (DDX) family members have also been linked to tau pathology in the rTg4510 
mouse model of tauopathy (Maziuk et al., 2018). These proteins appear to preferentially 
associate with small tau inclusions rather than large NFTs, suggesting that their role in 
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the disease etiology may be prior to tangle formation. Here we present optimized 
methods for the visualization of RBPs in murine brain tissue which reveal unique 
localization patterns of canonically nuclear RBPs in different brain regions of C57Bl/6 
mice. Importantly, these proteins show notable changes in their localization prior to tau 
tangle formation in the PS19 mouse model of tauopathy, and these localization changes 
become more pronounced as tauopathy progresses. Overexpression of TIA1 protein in 
this mouse model also substantially enhanced the accumulation of phosphorylated tau in 
the hippocampus at 4 months of age, further underscoring the importance of these 
proteins in early tau pathogenesis. Ultimately our findings continue to support the 
conclusion that RBPs are a critical component of tau pathology and remain a major new 
therapeutic target area for these diseases. 
Results 
RNA binding protein histology is highly sensitive to tissue fixation methods 
 Fixation is the first step in preparing tissue for histology and is required for 
preserving the molecular and morphological integrity of a sample. Typical fixatives 
include methanol or paraformaldehyde (PFA), which work by either dehydrating and 
precipitating protein or crosslinking proteins together, respectively (Howat & Wilson, 
2014). While drop fixation of brain tissue in 4% PFA for 24 hours is a common technique 
for preparing brain hemispheres for sectioning, we have previously reported that lengthy 
drop fixation yielded poor staining of TIA1 in rTg4510 mouse brain (Maziuk et al., 
2018); we have now extended these findings and report that drop fixation is unsuitable 
for the visualization of a variety of RBPs in brain tissue samples (Fig. 25). When brain 
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hemispheres were extracted and drop fixed overnight in 4% PFA, many RNA binding 
proteins including TIA1, G3BP1, HNRNPA0, and TDP-43 displayed minimal detection 
above background. When wild- type C57Bl/6 mice were instead perfused with 20mL of 
4% PFA over 10 minutes with hemispheres drop fixed for 1 hour after extraction, robust 
detection of these proteins by immunohistochemistry was observed (Fig. 25A). While 
DDX5 did stain positively for a fraction of neurons in drop-fixed tissues, many neurons 
were unlabeled (yellow arrows) (Fig. 25B). Perfusion fixed tissue yielded complete 
staining in all hippocampal neurons present. 
These findings extend into human brain samples, where short fixation periods are 
optimal for the staining of particular RBPs (Fig. 26). 0.5cm2 brain chunks were 
graciously provided by Dr. John Crary at the Icahn School of Medicine at Mount Sinai 
and fixed for either 1 hour, 2 hours, or 24 hours in 4% PFA at 4°C. HNRNPA0, an RBP 
involved in the post-transcriptional regulation of mRNA (Myer & Steitz, 1995), shows a 
complete loss of reactivity after 24 hours of fixation but robust detection with only 1 
hour. In particular, the short 1-hour fixation time also revealed cytoplasmic granules of 
this protein, which is of paramount importance when investigating the formation of stress 
or other ribonucleoprotein (RNP) granules in human disease. In contrast, human TDP-43 
was resistant to fixation effects, suggesting that different RBPs have different sensitivities 
to fixation. Finally, we also note that short fixation with periodate-lysine-
paraformaldehyde (PLP) is optimal for the drop fixation of human tissues (Fig. 27). PLP 
fixed tissues showed better neurite reactivity for RBPs such as DDX5 than tissues fixed 
with simple 4% PFA, and should be used when possible. 
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Figure 25: : Perfusion fixation yields optimal staining of RNA binding proteins in brain 
tissue. 
Immunohistochemistry of RNA binding proteins in either perfusion fixed or drop fixed mouse tissue 
reveals that perfusion fixation is required for the reproducible staining of these proteins in the brain. Mice 
were perfused either with 4% paraformaldehyde (PFA) or PBS; the brains of mice perfused with 4% PFA 
were drop fixed for an additional 1 hour in PFA while the mice perfused with PBS were drop fixed 
overnight in 4% PFA. Brains drop fixed overnight (A, top) had minimal reactivity with many RBPs 
including G3BP1, TIA1, TDP-43, and HNRNPA0. In contrast, robust staining was observed in mice which 
were fixed via perfusion. While DDX5 showed reactivity in drop fixed tissues, a substantial number of 
neurons did not stain (B, yellow arrows). Furthermore, perfusion fixation yielded exquisite preservation of 
morphology, indicating that DDX5 exists primarily at the nuclear envelope instead of throughout the 
nucleus. 
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Perfusion fixation reveals unique localization patterns of canonically nuclear RBPs  in 
different brain regions 
 Typically, RBPs such as TIA1, HNRNP family members, and DDX family 
members show prominent nuclear localization as they have various functions in RNA 
genesis and maturation (Keene & Query, 1991) (Gustafson & Wessel, 2010) (I. Wang et 
al., 2014) (Maziuk et al., 2017); some of these proteins also show low levels of 
cytoplasmic localization since they transport mRNAs through the cell. TIA1 in particular 
may become highly cytoplasmic under conditions of translational stress (N. L. Kedersha 
et al., 1999). Cytoplasmic TIA1 functions as stress granule nucleating factor, where it 
recruits stalled 40s ribosomal subunits, mRNA and other RBPs into a stress granule while 
the stress is dealt with; once the stress is alleviated, stress granules readily disperse and 
TIA1 returns to the nucleus (Anderson & Kedersha, 2002). 
Using our optimized perfusion fixation protocol, we find that traditionally nuclear 
RBPs such as HNRNPA0, DDX5, and TIA1 exhibit different localization patterns in 
different areas of the mouse brain (Fig. 28). In cortical layers 2/3, all three proteins 
displayed typical strong nuclear localization with minimal cytoplasmic reactivity. In the 
hippocampus, however, all three proteins showed significant basal expression in the 
cytoplasm of CA1 neurons and granule cells of the dentate gyrus. For both DDX5 and 
HNRNPA0, the highest reactivity was observed around the nuclear envelope. According 
to the Allen Brain Atlas, the hippocampus also displays the highest expression levels of 
TIA1 and DDX5 mRNA in the brain (Fig. 29, HNRNPA0 data not available); this in situ 
expression data together with our immunohistochemistry results begin to suggest nuanced 
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and unknown cytoplasmic roles for these RBPs in the function of hippocampal neurons 
compared to other brain regions. This may be of particular importance when considering 
the currently unknown mechanisms that make the hippocampus particularly sensitive to 
the development of tauopathies such as AD (K. S. Anand & Dhikav, 2012). 
 
 
 
Figure 26: Short fixation times optimally preserve RNA binding proteins in human brain 
tissues 
0.5cm2 samples of human brain were drop fixed in 4% PFA for either 1 hour, 2 hours, or 24 hours and 
analyzed by immunohistochemistry for RBP reactivity. While some RBPs, such as TDP-43 (bottom) show 
even reactivity, others such as HNRNPA0 showed substantial sensitivity to the fixation time, where longer 
fixation yielded poorer staining. With only 1 hour of fixation cytoplasmic granules were also detectable, 
indicating that these shorter fixation times are of paramount importance when studying ribonucleoprotein 
granule formation in human samples. 
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Figure 27: Periodate-lysine-paraformaldehyde (PLP) fixation is optimal for human brain 
tissue. 
Analysis of human tissue samples fixed with either 4% PFA (left) or PLP (right) revealed that PLP fixation 
yielded greater preservation of RBP reactivity (red) and morphology. The RBP DDX5 was clearly 
detectable in the neurites of PLP fixed sample but not in the PFA fixed sample. 
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Figure 28: Perfusion fixation reveals specific brain region localization patterns for 
canonically nuclear RNA binding proteins. 
Immunohistochemical analysis of multiple RNA binding proteins including HNRNPA0 (left), DDX5 
(middle), and TIA1 (right) in perfusion fixed mouse brain tissue indicates that the localization patterns of 
these proteins differ based on the brain region analyzed. In layers 2/3 of the cortex (top row), all three 
proteins show a classic strong nuclear localization signal. However, in the hippocampus strong nuclear 
envelope localization is observed in the CA1/2 region (middle row) and strong cytoplasmic localization is 
observed in the granule cells of the dentate gyrus (bottom row).  
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Figure 29: RNA binding proteins show highest mRNA levels in the hippocampus in mouse 
brain. 
Expression levels of TIA1 (left) and DDX5 (right) from in situ hybridization data provided by the Allen 
Brain Atlas (https://mouse.brain-map.org/) shows that these RBPs have their highest expression levels in 
the hippocampus of the mouse brain. This correlates with the cytoplasmic distribution patterns of these 
proteins also found in the hippocampus. Data for HNRNPA0 was not available. 
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Loss of nuclear TIA1 reactivity corresponds with axonal tau pathology early in disease 
The earliest described events in tau pathogenesis involve the dissociation of tau 
monomers from microtubules, usually due to phosphorylation or other post-translational 
modifications; as cytoplasmic monomers accumulate they begin to misfold and 
mislocalize to the somatodendritic compartment. We have found that cytoplasmic export 
of TIA1 and stress granule formation coincides with these early pathological events, 
establishing previously reported TIA1 pathology as important to the early stages of 
disease. Originally developed by Lee and Trojanowski (Yoshiyama et al., 2007), the 
PS19 mouse line expresses P301S human mutant tau at five times endogenous tau levels 
under control of the prion promoter. Yoshiyama et al. originally reported that 
microgliosis and synaptic loss precede tangle formation in the hippocampus of these 
mice; however, our improved fixation methods now reveal accumulation of 
phosphorylated and misfolded tau in the axons of CA3 hippocampal and cortical neurons 
in PS19 tauopathy mice as early as 3 months of age (Fig. 30). The discovery of early 
axonal tau pathology provides a missing link into tau pathogenesis; since tau is normally 
an axonal microtubule associated protein, we show that pathological tau does accumulate 
in the axons PS19 mice before entering the somatodendritic compartment. 
 Having previously reported that the stress granule protein TIA1 synergistically 
aggregates with tau in vitro (Vanderweyde et al., 2016), that reduction of TIA1 in vivo 
protects against tau-mediated neurodegeneration (Apicco et al., 2017), and that TIA1 is 
required for the propagation of toxic tau oligomers (Jiang et al., 2019), we now also show 
that a loss of nuclear TIA1 precedes tau tangle formation in a mouse model of tauopathy  
  
85 
 
 
Figure 30: Phosphorylated tau accumulates in axons of 3 month old PS19 mice and 
progresses to fibrillary tangles by 9 months. 
Immunohistochemical analysis of 3 month old PS19 mice revealed accumulations of AT8 positive 
phosphorylated tau (green) in neuronal axons throughout the brain. In particular, the CA2/3 hippocampus 
shows substantial tau accumulation, while cortical neurons show early granule formation. This pathology 
develops into mature fibrillar tangles by 9 months of age in the hippocampus (bottom) and cortex (top 
right, white arrows). 
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but corresponds with the accumulation of misfolded and phosphorylated axonal tau (Fig. 
31). We found the average nuclear expression of TIA1 in CA2/3 neurons for 3 month old 
PS19 mice was significantly lower than wild-type littermates (Fig. 31). TIA1 is normally 
exported from the nucleus into the cytoplasm where it acts to nucleate stress granules 
under conditions of translational stress (Kedersha et al., 1999); we have also found that 
the reduced nuclear TIA1 corresponds with higher cytoplasmic localization which is 
consistent with this biology. Granule formation was also evident throughout the 
hippocampus of PS19 mice. Together with our identification of misfolded soluble tau in 
CA3 area, discovering that TIA1 is exported to the cytoplasm early in tau pathogenesis 
supports the idea that tau-TIA1 stress granule formation and aggregation may mediate 
neurodegenerative effects.  
Progression of tau pathology involves a loss of nuclear integrity 
 Recently, it has been shown that disruption of the nuclear pore, nuclear transport, 
and the nuclear membrane are all pathologies of AD or FTD mediated by tau pathology 
(Eftekharzadeh et al., 2018) (Paonessa et al., 2019). This is evident through the 
mislocalization of particular nucleoporins such as Nup98, changes in nuclear pore 
permeability, and deficits in Ran-mediate nuclear transport in tauopathies. Knowing this, 
we also sought to identify if and at what time point this pathology is evident in the PS19 
mouse model and how it may coincide with RBP deregulation. We have found that in 
addition to TIA1, the nuclear RBPs DDX5 and HNRNPA0 show significant alterations in 
their nuclear localization by 3 months of age which then progresses with disease (Fig. 
32). Interestingly, while both proteins show strong association with the nuclear envelope,  
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Figure 31: Cytoplasmic localization of TIA1 occurs in tandem with phospho-tau 
accumulation early in tau pathogenesis. 
Immunohistochemical analysis of hippocampal TIA1 in young (3 month) PS19 indicated that TIA1 is 
exported from the nucleus to the cytoplasm in tandem with early tau pathology. Strong nuclear signal of 
TIA1 was observed in WT mice with a significant reduction occurring in PS19 mice (top graph, p = 
0.0057). A corresponding increase in cytoplasmic TIA1 (white arrows) was also observed in PS19 mice 
compared to WT (bottom graph, p = 0.023).  
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Figure 32: Changes in Nuclear RNA binding proteins precede disruption of the nuclear 
envelope. 
Similarly to TIA1, the typically nuclear RNA binding proteins HNRNPA0 and DDX5 show changes in 
hippocampal intracellular localization early in disease onset. Immunohistochemical analysis indicated that 
DDX5 shows lower nuclear expression levels in 3 month old PS19 mice compared to WT (A, top row, 
white arrows), while HNRNPA0 showed a notable increase (middle row, white arrows); in WT mice, 
HNRNPA0 displayed strong nuclear envelope localization, while PS19 mice showed nuclei accumulating 
HNRNPA0. However, disruption of the nuclear lamina indicated by lamin B2 staining was not evident at 
this age and was only evident beyond 6 months of age (bottom row, white arrows). 3 and 6 month WT 
shows equivalent expression of these proteins, and so the 3 month WT was omitted from this figure. Single 
cell images of the changes described are shown in (B), right. 
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DDX5 appears to lose nuclear localization in hippocampal neurons while HNRNPA0 
shows an increase in its total nuclear fluorescence. These immunohistochemical findings 
were confirmed by nuclear fractionation of brain regions from a separate mouse cohort at 
7 months of age (Fig. 33). At this age PS19 mice showed a trending decrease in nuclear 
TIA1 expression, but a significant decrease in nuclear DDX5 expression and increase in 
nuclear HNRNPA0. Importantly these changes were limited to the hippocampus; by this 
age tau pathology has not significantly developed in the cortex, and no cortical changes 
in these proteins were observed. 
  These changes also precede the tau (mediated) disruption of the nuclear envelope 
reported by others (Fig. 32). We have found that significant alterations of the nuclear 
lamina as indicated by lamin B2 immunohistochemistry are evident by 6 months of age in 
the CA2/3 hippocampus. Consequently, the loss of nuclear proteins such as DDX5 or 
exportation of proteins such as TIA1 is likely not due to a physical breakdown of the 
barriers which compartmentalize them. Rather, it appears that proteins have a more direct 
and active relevance to early tau pathology which remains to be elucidated. 
Overexpression of TIA1 in vivo accelerates hippocampal tau pathology 
 Our lab previously demonstrated that in vivo reduction of TIA1 extended the 
survival of PS19 mice and rescued behavioral and molecular deficits (Apicco et al., 
2017). As we have now shown that cytoplasmic accumulation of TIA1 is a pre-NTF 
pathology in tau pathogenesis, we looked to also see if overexpression of TIA1 in vivo 
had any impact on the development of tau pathology. To this end, we used 
intracerebroventricular (ICV) injections of AAV virus in P0 mouse pups to stably 
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overexpress fluorescent human TIA1 in adult mouse neurons (Fig. 34). Remarkably, 
overexpression of TIA1 was found to substantially accelerate the accumulation of  
somatodendritic phosphorylated tau in hippocampal neurons at four months of age (Fig. 
35); more injected animals are now being aged in order to continue this study with 
multiple stages of disease. Exogenous TIA1 also appeared to colocalize with MC1 
positive tau granules stained in green (Fig. 36), which was visualized in an antibody 
independent manner using its far-red miRFP tag (magenta). This is in line with previous 
reports of TIA1-tau colocalization (Vanderweyde et al., 2012) (Maziuk et al., 2018) and 
continues to suggest a critical role of TIA1 positive stress granules as a nidus of tau 
pathology. 
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Figure 33: Changes in nuclear DDX5 and HNRNPA0 expression were confirmed by nuclear 
fractionation. 
Changes in nuclear DDX5 and HNRNPA0 was confirmed by biochemical nuclear fractionation of 7-month 
old PS19 (n = 3) and WT (n = 2) mice. The cortex (right) and hippocampus (left) of each mouse was 
extracted, nuclei were separated from the cytoplasmic fraction using a series of centrifugations, and the 
resulting fractions were probed by western blot. While TIA1 changes were only trending (p = 0.389) by this 
age, a significant reduction in hippocampal nuclear DDX5 was observed (p = 0.0495) and a significant 
increase in HNRNPA0 was also confirmed (p = 0.0026) following normalization to Histone H1 levels. 
These changes were not evident in the cortex of the same mice (right blots, graphs not shown). 
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Figure 34: Intracerebroventricular (ICV) injection of AAV9 virus encoding miRFP::TIA1 
leads to the stable neuronal expression of far-red fluorescent TIA1 protein. 
P0 mouse pups injected with 2uL of 1e10 genomes of AAV9 virus (diagram, left) stably expressed tagged 
TIA1 protein (top right, purple) in cortical and hippocampal neurons at 4 four months of age. 
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Figure 35: PS19 mice overexpressing TIA1 show accelerated accumulation of hippocampal 
tau pathology. 
4 month old PS19 mice either injected or uninjected with the miRFP::TIA1 AAV9 virus were assessed by 
immunohistochemistry for hippocampal tau pathology. We found that overexpression of the TIA1 
significantly accelerated the accumulation of phosphorylated tau (AT8, p = 0.0012; PHF1, p = 0.0331) but 
not misfolded tau (MC1, p = 0.5254) in the hippocampus. Substantial somatodendritic pathology was 
observed in these mice, while no somatodendritic pathology was observed in non-injected PS19 mice at 4 
months of age.  
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Figure 36: Exogenous TIA1 granules colocalize with pathological tau granules in PS19 mice. 
The fluorescently tagged TIA1 formed granules in PS19 mice which colocalized with small 
somatodendritic MC1-positive tau inclusions (white arrows).  
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Discussion 
 In recent years, RBPs have emerged as a class of proteins strongly tied to 
neurodegenerative disease (Maziuk et al., 2017). While our lab has recently shown that 
TIA1 is strongly linked to tau pathology, we and others have noted difficulty in assessing 
TIA1 and other RBPs immunohistochemically; often these studies require multiple 
antibodies and meticulous optimization to observe signal. Our finding that RBP detection 
shows considerable sensitivity to tissue fixation may be critical in evaluating current 
tissue processing practices and advancing the study of these proteins in brain samples. 
Additionally, fixation methods can impact the study of well-known pathologies such as 
tau hyper-phosphorylation optimal fixation permits us to detect axonal tau 
phosphorylation as the earliest marker of disease. 
With this preliminary work in mind, we are now working to establish an AD brain 
bank of short fixed tissue samples in collaboration with multiple AD centers including 
Mayo Clinic, Mount Sinai, and Houston Methodist. Because these tissue samples must be 
obtained from a fresh autopsy, these centers have agreed to sample three Brodmann areas 
of AD and control brain tissues as they are available and fix them using our optimized 
short time periods in PLP media. The creation of this bank will be critical for moving 
past the technical limitations of overfixed human tissue in evaluating RBP pathology in 
human disease. 
 Our data also lend further support to a model where cytoplasmic localization of 
RBPs in tandem with stress granule formation is a critical feature of early tau 
pathogenesis. Our previous studies have indicated that TIA1 facilitates tau aggregation in 
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vitro (Vanderweyde et al., 2016), that reduction of TIA1 in vivo is protective against tau 
mediated neurodegeneration (Apicco et al., 2017), that TIA1 is required for the 
propagation of toxic oligomeric tau species (Jiang et al., 2019), and that tau shows 
disease relevant changes in its association with ribosomal and RNA binding proteins 
(Maziuk et al., 2018). The work presented here now extends these findings to show that 
nuclear RBP deregulation is an early pathology coincident with the accumulation of 
phosphorylated tau, and that overexpression of the RBP TIA1 accelerates disease 
progression in vivo.  
 These findings fit well into the emerging idea that the progression of tauopathies 
involves a serious breakdown of nuclear integrity and mRNA metabolism. Recent studies 
from multiple groups have demonstrated that invagination of the nuclear lamina, 
disruption of the nuclear pore, and aberrant nuclear transport result from neuronal tau 
aggregation (Eftekharzadeh et al., 2018) (Paonessa et al., 2019). Consistent with these 
reports, our study has also identified lamina disruption in PS19 mice, but at a later stage 
of disease; cytoplasmic localization of TIA1 as well as changes in DDX5 and HNRNPA0 
expression were found to occur before this, placing them as earlier stage pathologies of 
tauopathy progression.  
Thus, rather than passing directly through a disrupted nuclear lamina, these early 
changes in RBPs may arise from a “leaky” nuclear pore, inefficient shuttling of proteins 
back into the nucleus, or a more active stress mechanism of cytoplasmic localization in 
response to tau. It may also be that observed breakdowns in nuclear function may be an 
effect of a prolonged TIA1 mediated stress response; there is recent precedent for this in 
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work done with TDP-43, where cytoplasmic TDP-43 droplets recruit the nuclear 
transport factors importin-α and Nup62 and inhibit nucleocytoplasmic transport (Gasset-
Rosa et al., 2019). Nup62 also colocalizes with phosphorylated tau in AD brains 
(Eftekharzadeh et al., 2018) and TIA1 positive stress granules under sodium arsenite 
induced stress in vitro (Hochberg-Laufer et al., 2019), which further connects TIA1 
granule formation to tau mediated neurodegeneration.  
 In tandem with the reports of breakdowns in nuclear transport and stability, other 
groups have recently established that tau mediated neurodegeneration involves 
substantial disruptions in mRNA splicing and translation (Hsieh et al., 2019; Koren et al., 
2019; Evans, Benetatos, van Roijen, Bodea, & Götz, 2019).  These groups suggest that 
tau associates with both the spliceosome and ribosome and acts to perturb the functions 
of these complexes; tau both promotes pre-mRNA splicing errors by the spliceosome and 
massively downregulates protein synthesis at the ribosome, particularly of new ribosomal 
proteins. While these two biological processes are seemingly disparate events, RBPs 
represent a major mechanistic link between them. TIA1 in particular is both a splicing 
factor responsible for mediating 5' splice site recognition by the U1 small nuclear 
ribonucleoprotein (Gunawardana et al., 2015) known to aggregate in AD (Hales et al., 
2014) and a cytoplasmic stress granule nucleation factor activated by recognition of 
stalled 40S ribosomal subunits (N. L. Kedersha et al., 1999). As pathological tau also 
closely associates with ribosomal proteins (Maziuk et al., 2018) (Meier, Bell, Lyons, 
Rodriguez-Rivera, et al., 2016), TIA1 and other RNA binding proteins are an auspicious 
mechanistic link between tau aggregation and these multifaceted cytotoxic effects. 
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 We have also now shown that overexpression of TIA1 accelerates the 
accumulation of tau pathology in PS19 mice, consistent with our findings that reduction 
of TIA1 in these mice is protective (Apicco et al., 2017). While not all tau granules were 
found to contain exogenous TIA1, not all neurons were found to express the fluorescent 
TIA1 construct. Additionally, individual pathological tau proteins can exhibit a wide 
variety of variable features such as particular post-translational modifications, 
conformations, or aggregation states (Y. Wang & Mandelkow, 2016). TIA1 and other 
RBPs may consequently not interact with all tau; rather, association may be dependent on 
a particular modification, conformation, or oligomerization state, and efforts must be 
made to determine the molecular nature of these interactions. 
In 2017 our lab also reported that reduction of TIA1 reduced oligomeric tau but 
increased fibrillar tau (Apicco et al., 2017), and having also recently shown that TIA1 is 
required for the propagation of oligomeric tau in vivo (Jiang et al., 2019), we postulate 
now that TIA1-tau de-mixing may lead to the formation or stabilization of toxic 
oligomeric tau species in AD. The Mandelkow, Taylor and Hyman laboratories have 
collaboratively demonstrated that tau droplets can be observed in neurons (Wegmann et 
al., 2018), and this liquid-liquid phase separation of tau is promoted by RNA interactions 
(X. Zhang et al., 2017). We have previously shown that TIA1 granule formation facilities 
tau aggregation (Vanderweyde et al., 2016) and now find that early tau pathology leads to 
cytoplasmic re-distribution of TIA1 in vivo. Thus, efforts should now be made to 
understand the relationship between RBP and tau droplets as well as the impact one has 
on the other.  
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 Our findings continue to support the idea that the formation of ribonucleoprotein 
granules is a major contributing factor to tau pathogenesis. At the earliest stages of 
disease, we find that TIA1 leaves the nucleus and enters the cytoplasm of neurons in 
regions displaying phospho-tau accumulation. As disease progresses, we observe further 
disruption of nuclear RBP regulation, which parallels published findings that tau 
mediated neurodegeneration involves a severe deregulation of nuclear transport. 
Overexpression of the RBP TIA1 also drives tau phosphorylation and accumulation in 
neurons, which is analogous to our previous report that reduction of TIA1 is protective 
against tauopathy. RBPs therefore represent a promising novel target for therapeutic 
intervention in these diseases. 
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CHAPTER THREE 
Conclusion: RNA binding proteins are a critical component of early tau 
pathogenesis 
 
Summary of Results 
 Over the last decade, an ever expanding body of work has firmly linked RNA 
binding proteins (RBPs) to neurodegenerative disease (Maziuk et al., 2017). While our 
laboratory was one of the first to establish RBP pathology as a feature tauopathy, critical 
questions have remained regarding both the technical and mechanistic challenges of 
studying this group of proteins in tau mediated neurodegeneration; reproducing 
immunohistochemical findings in tissue samples has proven inconsistent, and as of yet no 
in vivo data has conclusively ascertained whether RBP changes are a driver of early 
disease versus late stage pathology. To these ends, we show here that tissue fixation 
methods have a profound impact on the ability to stain and visualize RNA binding 
proteins in brain samples, that RNA binding proteins show disease relevant changes in 
their binding and association to tau early in disease, and that nuclear deregulation of 
RBPs is an early stage pathology of tauopathy which precedes tau tangle formation. 
 Using both human and mouse brain tissues, we have definitively shown that 
longer periods of tissue fixation results in an inability to stain many RBPs 
immunohistochemically. This was first noticed when brain hemispheres were drop fixed 
for either 24 or 48 hours in formalin and stained for NeuN and TIA1; 24 hour fixed tissue 
had substantially more signal for both proteins. The impact of long fixation was also 
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confirmed in human tissues, where tissue chunks drop fixed for only 1 or 2 hours had 
staining for certain RBPs such as HNRNPA0. Following this, we also compared mouse 
tissues either drop fixed with 4% PFA for 24 hours or perfusion fixed with only 1 hour of 
drop fixation post-perfusion. Tissues that were fixed by perfusion showed remarkable 
RBP labeling and preservation of cellular architecture compared to drop fixed brains. The 
influence of longer fixation on tissue staining also extended to tau pathology, where 
immunohistochemistry of perfusion fixed brains revealed previously unreported early 
accumulation of phosphorylated and misfolded tau in the axons of hippocampal and 
cortical neurons in PS19 mice. Such a finding may have dramatic impacts on how 
neuropathologists everywhere process future human tissues for Alzheimer’s disease 
research and other neurological diseases. 
 Using biochemical techniques alongside our optimal fixation methods, we 
proceeded to demonstrate that RBPs associate closely with pathological tau early in two 
different mouse models of disease and human tissues. In the rTg4510 mouse model of 
tauopathy, mass spec of immunoprecipitated mutant tau uncovered many ribosomal and 
RBPs which associate with tau and change in those associations with disease progression. 
Furthermore, these proteins also display increasing insolubility in disease and colocalize 
with diffuse phospho-tau in the soma of cortical neurons. Interestingly, however, these 
proteins lost their colocalization with tau as it formed mature NFTs and instead showed 
exclusion from tangles; this was also true in late stage human tissue, where RBP 
aggregates accumulated at the edges of NFTs instead of within.  
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 From this and other work, we hypothesized that RBPs were more involved in 
early tau pathogenesis and aggregation rather than in later stage fibrillization. Using the 
PS19 mouse model of tauopathy, which develops tau pathology more slowly and less 
aggressively than the rTg4510 model, we have established that cytoplasmic export of 
TIA1 is coincident with early accumulation of axonal phosphorylated tau in CA3 
hippocampal neurons. Overexpression of fluorescent TIA1 in these mice greatly 
accelerated this tau accumulation, and granules of this TIA1 associated with 
somatodendritic phospho-tau granules. Deregulation of other nuclear RBPs DDX5 and 
HNRNPA0 as well as the nuclear lamina also progressed with disease between 3 and 6 
months of age; all of these findings occur prior to the formation of any neurofibrillary 
tangles. 
Conclusions 
 Ultimately our results lend additional support to our hypothesis that TIA1 and 
other RBPs are important components in the progression of Alzheimer’s disease and 
related tauopathies. While we have previously reported that TIA1 promotes tau 
aggregation in vitro, we now have also found that early changes in TIA1 localization are 
evident in young PS19 mice and that TIA1 promotes tau aggregation in vivo. This has led 
us to an evolved model of tau pathogenesis where early tau modifications lead to 
cytoplasmic RBP localization which in turn contributes to further tau aggregation, 
propagation, and cytotoxic effects (Fig. 37). First, upstream signaling cascades lead to the 
phosphorylation of axonal tau and cause it to dissociate from microtubules (Fig. 37-1). 
As it dissociates it accumulates in the cytosol, and at this time TIA1 is exported from the 
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nucleus to the cytoplasm (Fig. 37-2). This leads to the interaction of tau with TIA1 and 
other RBPs in the neuronal soma, which in turn promotes the formation of stable higher 
order tau aggregates (Fig. 37-3). As these aggregates develop, they may 1) mediate 
cytotoxicity via disruption of splicing, translation, or nuclear transport, 2) propagate to 
other neurons (Fig. 37-4) (Jiang et al., 2019), or 3) continue to aggregate into beta-sheet 
containing structures such as NFTs (Fig. 37-5). These fibrils no longer contain RBPs 
directly, instead exhibiting exclusion of these proteins by immunohistochemistry (Maziuk 
et al., 2018).  
 Such a model mechanistically fits well with other emergent work in tau mediated 
neurodegeneration including work on tau liquid-liquid phase separation (Wegmann et al., 
2018), the impacts of tau on the ribosome and protein translation (Koren et al., 2019) 
(Evans et al., 2019), and the association of tau with the spliceosome (Hsieh et al., 2019). 
RBPs have strong biological ties to all of these processes, and thus may mediate many if 
not all of these observed effects in disease as discussed in Chapter 2. In particular, RNA 
greatly enhances the ability of tau to form liquid droplets, and the mRNA rich 
environment of a stress or similar RNP granule is a biological setting which may satisfy 
the requirements for such droplet formation (Wolozin & Ivanov, 2019). As liquid 
droplets turn to gels, biological processes related to these proteins may in turn become 
dysfunctional; that would include splicing, translation, and nuclear transport, all of which 
require RBPs to function normally. 
 Our model also fits well in the new body of work highlighting tau oligomers as a 
major, if not the major, driver of neurotoxicity and disease. Beginning with Santa Cruz et 
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al (2005), there has been a major push in understanding how lower-order tau aggregates 
contribute to the disease process. Since then oligomers have been clearly established as a 
toxic tau species (Ward et al., 2014) (Ward et al., 2012), but the processes underlying 
their formation and toxicity are not clear. Our recent work indicates that tau oligomers 
propagate in a TIA1 dependent manner and that TIA1 may be responsible for oligomeric 
tau formation or stabilization (Apicco et al., 2017). We have updated our model to 
incorporate these new results, where the newly identified early mislocalization of TIA1 
into the cytosol may in turn facilitate the oligomerization of free monomeric tau as it 
diffuses from the axon into the somatodendritic compartment (Fig. 37, #3).  
Ultimately, this work continues to place tauopathy in the spectrum of 
neurodegenerative diseases characterized by protein aggregation linked to chronically 
active cellular stress pathways. Amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia (FTD) are two major neurodegenerative diseases with well-established 
proteinopathies related to stress granule signaling and RBPs; these proteins include TDP-
43, FUS, EWS, TIA1, ATXN2, HNRNPA1/2, and MATR3 (Wolozin, 2012). While 
TDP-43 aggregation can be coincident with tau in FTD patients (Behrouzi et al., 2016), 
TDP-43 aggregation is generally not seen in AD or other tauopathies. We have recently 
postulated that these separate pathologies may be related to distinct stress signaling 
pathways involving RBPs (Wolozin & Ivanov, 2019), and more work remains to define 
these molecular pathways and key proteins involved. Below we discuss strategies to 
investigate these questions and others which have arisen from this work. 
  
  
105 
 
Figure 37: An updated model of tau pathogenesis features RNA binding proteins (RBPs) as 
major contributors towards tau aggregation, propagation, and neurotoxicity. 
It is well established that the earliest events in the development of tauopathy are the hyper-phosphorylation 
of tau, dissociation of tau from microtubules, and accumulation of this dissociated monomeric tau in the 
cytosol (1). Our work now supports a model where this accumulation of tau leads to export of TIA1 from 
the nucleus into the cytoplasm early in disease (2) where these RBPs then form granules and associate with 
phospho-tau (3). As RBPs interact with tau, they facilitate both its aggregation into higher order species 
such as oligomers and the propagation of these oligomers to other neurons (4). Eventually, the tau will 
mature into fibrillar tangles which no longer interact with RBPs; RBPs instead accumulate at the periphery 
of mature tangles. Importantly, the formation of persistent ribonucleoprotein granules with tau may lead to 
dramatic changes in nuclear integrity, nuclear transport, mRNA splicing, mRNA transport, and/or mRNA 
translation beginning as early as stage 3.  
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Future Directions 
 It is important now to continue diligent investigations on the biophysical 
mechanisms underlying tau and RBP association as well as the impacts these associations 
have on cellular health. Strategies for addressing many of these questions are discussed 
below: 
1. Following our work identifying the need for short fixation of human brain 
samples, we are now working with collaborators at Mount Sinai, Houston 
Methodist, and the Mayo Clinic to generate a repository of AD and control brain 
samples fixed for up to 2 hours in PLP media. Once collected, these brain samples 
will allow us to visualize RBP deregulation and granule formation with 
unprecedented clarity in human disease.  
2. Affinity purification studies from us and others have shown a close association 
between tau, ribosomal proteins, and RNA binding proteins in disease (Maziuk et 
al., 2018) (Koren et al., 2019). Work must now be done to determine which of 
these proteins have the closest association to pathological tau and how these 
associations influence larger ribonucleoprotein (RNP) complexes. To this end we 
propose the use of proximity labeling techniques such as TurboID or Apex2 in 
conjunction with tau to validate tau-RBP interactions and identify proteins 
interacting closest with tau (Trinkle-Mulcahy, 2019) (Branon et al., 2017). 
Proximity labeling techniques employ the use of enzymatic tags on a protein of 
interest to biotinylate proteins within a 10-20nm radius; biotinylated proteins can 
then be isolated with downstream purification methods and identified with tandem 
  
107 
mass spectrometry. By expressing tau tagged with Apex2, for example, only 
proteins within a 20nm distance of tau become biotinylated and identifiable. 
Expression of these tau constructs in either in vitro or in vivo disease models will 
allow for the robust identification of tau-RBP complexes as well as changes in 
these complexes in different disease stages. 
3. Second, establishing the binding mechanisms between tau and RBPs is an 
important step towards therapeutic intervention in this area. As tau has many 
splice isoforms containing varying microtubule binding and/or projection domains 
(Fig. 5), it is important to identify which of these domains are critical for binding 
RBPs. In silico and in vitro binding assays can be used to determine which 
domains of tau regulate tau-RBP interaction. By expressing particular isoforms of 
tau, incubating with particular RBPs known to interact with tau, and affinity 
purifying tau, we can establish if RBPs co-precipitate with particular tau isoforms. 
We can also express these constructs in cells followed by immunoprecipitation for 
validation. Tau-RBP interactions may also be dependent on the oligomerization or 
phosphorylation state of tau, and so experiments may also include oligomerized or 
phospho-mimetic tau to determine if this is true. 
4. Liquid-liquid phase separation is an important biological mechanism established 
for both tau and RBPs (Zhang et al., 2017) (Wegmann et al., 2018) (Patel et al., 
2015) and may represent the major biophysical pathway through which RBPs 
facilitate tau aggregation. Tau droplets can be induced in vitro under 
physiological conditions by incubating recombinant tau with crowding reagents 
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such as heparin or RNA, and tau droplets are now also observable in neurons. If 
RBPs also facilitate tau droplet formation, then we expect the addition of 
recombinant RBPs such as TIA1 to the droplet reaction will increase the rate, 
size, and/or number of tau droplets formed. They may also influence the transition 
of tau from a liquid droplet to a gel, which can be determined through fluorescent 
mobility assays. The shift from a liquid to a gel is an important biochemical 
distinction representing the change from a reversible physiological aggregate to a 
more permanent, pathological aggregate; the influence of RBPs on this process 
may be an important piece of their role in tau pathogenesis. 
5. We also must establish if tau-mediated disruption of the spliceosome is RBP 
dependent. It has been shown that tau associates with the core spliceosomal 
proteins SmB and U1A which promotes cryptic splicing in AD (Hsieh et al., 
2019); unpublished work from our lab has also indicated that PS19 mice have 
severe deficits in mRNA splicing which can be corrected by TIA1 reduction. We 
thus propose the use of siRNA mediated depletion of key RBPs implicated in 
tauopathy to determine if these RBPs mediate observed splicing deficits in 
tauopathy. Key proteins include TIA1, DDX family members 3, 5, and 6, 
EWSR1, TAF15, and HNRNPA0. If reduction of these proteins restores splicing, 
then we would expect to see a reduction of cryptic splicing to baseline levels or a 
rescue of other alternative splicing events in PS19 mice, tauopathy drosophila 
models, or in vitro tauopathy models. 
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6. Finally, in addition to splicing deficits, abnormalities in protein translation 
mediated by pathological tau on the ribosome have been recently identified. 
Combining non-canonical amino acid labeling with depletion of specific RBPs 
may also reveal significant links between RBPs, tau, and protein translation. Non-
canonical amino acid labeling refers to the incorporation of labeled amino acids or 
small molecules into a peptide during its translation such that the newly 
synthesized peptide can be readily identified biochemically; this may done 
through methionine analogs such as azidohomoalanine (AHA) or puromycin. 
Puromycin can be used to label peptides both in vitro and in vivo (Koren et al., 
2019) to reveal changes in protein translation in the presence or absence of tau 
pathology. By combining this with a RBP depletion approach, new insights into 
the mechanisms underlying changes in protein translation during tauopathy may 
be revealed. Alternatively, use of translational ribosome affinity purification 
(TRAP) (Heiman, Kulicke, Fenster, Greengard, & Heintz, 2014) or ribosome 
profiling can be used to assessed protein translation in tauopathy. TRAP has the 
potential to reveal translational changes with cell-type specificity via the 
expression of eGFP tagged RPL10 protein driven by particular promoters; 
purification of these ribosomes using anti-eGFP antibodies can consequently 
reveal tau mediated changes in mRNA transcripts undergoing translation as well 
as ribosome composition. While it does not have the exquisite sub-cellular 
specificity of TRAP, ribosome profiling coupled with RNA sequencing and 
expression profiling may also reveal changes in both transcripts undergoing 
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translation and ribosome composition in tauoapathy; this may be particularly 
relevant in human tissues where eGFP-RPL10 cannot be expressed. 
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Dissertation highlights 
1. RNA binding proteins (RBPs) play a central role in the pathogenesis of multiple 
neurodegenerative diseases and have recently been implicated in tauopathies such 
as Alzheimer’s disease (AD). 
 
2. RBPs associate with pathological tau in a mouse model of AD and become 
insoluble as disease progresses. 
 
3. RBPs associate with tau prior to the formation of neurofibrillary tangles, but 
become excluded from mature tangles in both mouse and human tissue. 
 
4. Tissue fixation methods are critically important in preparing tissue for RBP and 
pathological tau immunohistochemistry. Shorter drop fixation times or the use of 
perfusion fixation are key for optimal staining of these pathologies. 
 
5. Cytoplasmic localization and loss of nuclear TIA1 occurs early in PS19 tauopathy 
mice; this is coincident with the accumulation of early phosphorylated tau 
pathology and precedes a loss of nuclear integrity as disease progresses. 
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6. Overexpression of TIA1 in PS19 mice accelerates the accumulation of 
pathological phospho-tau in disease. 
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APPENDIX I 
**Spectral counts normalized to 
hMAPT = 1000 
          
            
Protein Name (277) Gene ID 
Contl 
(Avg) 
Tg 
(Avg) 
Fold 
Change 
(Tg:Cntl) 
P Value 
Actin-related protein 2 Actr2 27.9 0.0 0.00 1.35E-01 
Isoform 18 of Disintegrin and 
metalloproteinase domain-containing 
protein 22 
Adam22 76.6 0.0 0.00 2.77E-02 
Aldose reductase Akr1b1 34.0 0.0 0.00 1.50E-01 
Isoform A1-III of V-type proton 
ATPase 116 kDa subunit a isoform 1 
Atp6v0a1 61.9 0.0 0.00 3.44E-02 
Adenylyl cyclase-associated protein 1 Cap1 61.9 0.0 0.00 3.44E-02 
Contactin-1 Cntn1 48.7 0.0 0.00 3.21E-02 
Drebrin Dbn1 34.0 0.0 0.00 1.50E-01 
Isoform 2 of Probable ATP-
dependent RNA helicase DDX17  
Ddx17 115.2 0.0 0.00 2.94E-02 
Erlin-2 Erlin2 34.0 0.0 0.00 1.50E-01 
Electron transfer flavoprotein subunit 
alpha, mitochondrial 
Etfa 27.9 0.0 0.00 1.35E-01 
Isoform Cytoplasmic of Fumarate 
hydratase, mitochondrial 
Fh 27.9 0.0 0.00 1.35E-01 
Fascin Fscn1 41.0 0.0 0.00 1.59E-01 
Rab GDP dissociation inhibitor alpha Gdi1 60.3 0.0 0.00 1.64E-01 
Guanine nucleotide-binding protein 
subunit alpha-11 
Gna11 47.1 0.0 0.00 1.38E-01 
Guanine nucleotide-binding protein 
G(q) subunit alpha 
Gnaq 82.7 0.0 0.00 5.77E-02 
Isoform 2 of Guanine nucleotide-
binding protein subunit beta-5 
Gnb5 48.7 0.0 0.00 3.21E-02 
Glucose-6-phosphate isomerase Gpi 61.9 0.0 0.00 3.44E-02 
Histone H2A  H2afz 35.5 0.0 0.00 1.43E-01 
Histone H4  Hist1h4a 79.7 0.0 0.00 2.01E-01 
Homer protein homolog 1  Homer1 35.5 0.0 0.00 1.43E-01 
Hypoxanthine-guanine 
phosphoribosyltransferase 
Hprt1 55.7 0.0 0.00 1.35E-01 
Isoform 2 of Isocitrate 
dehydrogenase [NAD] subunit alpha, 
mitochondrial  
Idh3a 29.4 0.0 0.00 1.34E-01 
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Isoform S-MAG of Myelin-associated 
glycoprotein 
Mag 27.9 0.0 0.00 1.35E-01 
Cytochrome b Mt-Cyb 34.0 0.0 0.00 1.50E-01 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 12 
Ndufa12 48.7 0.0 0.00 3.21E-02 
NADH dehydrogenase [ubiquinone] 1 
alpha subcomplex subunit 7 
Ndufa7 27.9 0.0 0.00 1.35E-01 
NADH dehydrogenase [ubiquinone] 1 
beta subcomplex subunit 4 
Ndufb4 27.9 0.0 0.00 1.35E-01 
NADH dehydrogenase [ubiquinone] 
iron-sulfur protein 7, mitochondrial 
Ndufs7 48.7 0.0 0.00 3.21E-02 
NADH dehydrogenase [ubiquinone] 
flavoprotein 1, mitochondrial 
Ndufv1 57.3 0.0 0.00 5.48E-02 
NEDD8 ultimate buster 1 Nub1 27.9 0.0 0.00 1.35E-01 
Succinyl-CoA:3-ketoacid-coenzyme A 
transferase 
Oxct1 63.4 0.0 0.00 8.63E-05 
Poly A binding protein, cytoplasmic 2 Pabpc2 63.4 0.0 0.00 4.41E-02 
Protein kinase C and casein kinase 
substrate in neurons protein 1 
Pacsin1 57.3 0.0 0.00 5.48E-02 
Isoform 2 of Poly(rC)-binding protein 
2 
Pcbp2 27.9 0.0 0.00 1.35E-01 
Propionyl-CoA carboxylase beta 
chain, mitochondrial 
Pccb 54.8 0.0 0.00 2.12E-01 
28 kDa heat- and acid-stable 
phosphoprotein  
Pdap1 50.2 0.0 0.00 1.43E-01 
Pyruvate dehydrogenase E1 
component subunit beta, 
mitochondrial 
Pdhb 89.7 0.0 0.00 3.69E-02 
D-3-phosphoglycerate 
dehydrogenase 
Phgdh 48.7 0.0 0.00 3.21E-02 
Peptidyl-prolyl cis-trans isomerase B Ppib 27.9 0.0 0.00 1.35E-01 
Major prion protein Prnp 63.4 0.0 0.00 8.63E-05 
Proteasome subunit alpha type-6 Psma6 48.7 0.0 0.00 3.21E-02 
Ras-related protein Rab-5C  Rab5c 56.4 0.0 0.00 2.01E-01 
60S ribosomal protein L12  Rpl12 65.0 0.0 0.00 1.73E-01 
60S ribosomal protein L26 Rpl26 27.9 0.0 0.00 1.35E-01 
60S ribosomal protein L30  Rpl30 29.4 0.0 0.00 1.34E-01 
60S ribosomal protein L8 Rpl8 27.9 0.0 0.00 1.35E-01 
60S acidic ribosomal protein P0  Rplp0 35.5 0.0 0.00 1.43E-01 
SH3-containing GRB2-like protein 3-
interacting protein 1 
Sgip1 27.9 0.0 0.00 1.35E-01 
Synaptosomal-associated protein 25 Snap25 131.4 0.0 0.00 2.88E-02 
Small nuclear ribonucleoprotein Sm 
D1 
Snrpd1 27.9 0.0 0.00 1.35E-01 
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Small nuclear ribonucleoprotein G Snrpg 48.7 0.0 0.00 3.21E-02 
Superoxide dismutase [Mn], 
mitochondrial 
Sod2 27.9 0.0 0.00 1.35E-01 
Signal recognition particle subunit 
SRP72 
Srp72 27.9 0.0 0.00 1.35E-01 
Serine/arginine-rich splicing factor 6 Srsf6 72.0 0.0 0.00 2.45E-01 
Syntaxin-1A Stx1a 76.6 0.0 0.00 2.77E-02 
Transketolase Tkt 34.0 0.0 0.00 1.50E-01 
Isoform 2 of Ubiquitin-associated 
protein 2-like 
Ubap2l 61.9 0.0 0.00 3.44E-02 
WD repeat-containing protein 1 Wdr1 92.8 0.0 0.00 1.77E-02 
Phosphoglycerate mutase 1 Pgam1 218.1 7.4 0.03 1.51E-03 
Phosphoglycerate kinase 1 Pgk1 218.1 8.1 0.04 2.38E-05 
Isoform 2 of 4-aminobutyrate 
aminotransferase, mitochondrial 
Abat 140.0 8.1 0.06 3.57E-03 
Heterogeneous nuclear 
ribonucleoprotein L 
Hnrnpl 113.6 7.4 0.06 2.12E-02 
Prohibitin Phb 106.0 7.6 0.07 1.14E-04 
ATP synthase F(0) complex subunit 
B1, mitochondrial 
Atp5f1 84.2 7.6 0.09 3.62E-02 
Serine/threonine-protein 
phosphatase PP1-gamma catalytic 
subunit 
Ppp1cc 68.9 7.4 0.11 1.16E-01 
Heterogeneous nuclear 
ribonucleoprotein R 
Hnrnpr 96.7 10.9 0.11 1.85E-01 
DnaJ homolog subfamily A member 
1 
Dnaja1 61.9 7.6 0.12 6.38E-02 
Isoform I of Septin-6 Sept6 55.7 7.4 0.13 1.94E-01 
Carbonic anhydrase 2 Ca2 55.7 8.1 0.14 2.02E-01 
Nucleolin  Ncl 71.1 10.9 0.15 2.17E-01 
Ubiquitin thioesterase OTUB1 Otub1 48.7 7.6 0.16 7.48E-02 
Zinc finger Ran-binding domain-
containing protein 2 
Zranb2 89.7 14.9 0.17 7.43E-02 
Cytochrome c oxidase subunit 2 Mtco2 135.4 23.0 0.17 4.39E-03 
Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, 
mitochondrial 
Sdha 197.2 33.6 0.17 1.86E-04 
Heterogeneous nuclear 
ribonucleoprotein Q 
Syncrip 159.2 29.9 0.19 6.65E-02 
Isoform ISO11 of Fragile X mental 
retardation protein 1 homolog 
Fmr1 57.3 10.9 0.19 3.22E-01 
V-type proton ATPase subunit E 1 Atp6v1e1 41.0 8.1 0.20 2.64E-01 
Glycerol-3-phosphate 
dehydrogenase, mitochondrial 
Gpd2 123.7 25.8 0.21 7.89E-02 
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Peroxiredoxin-6 Prdx6 70.4 14.9 0.21 9.50E-02 
3-ketoacyl-CoA thiolase, 
mitochondrial 
Acaa2 34.0 7.4 0.22 2.69E-01 
Coiled-coil-helix-coiled-coil-helix 
domain-containing protein 6, 
mitochondrial 
Chchd6 34.0 7.4 0.22 2.69E-01 
Small nuclear ribonucleoprotein Sm 
D2  
Snrpd2 50.2 10.9 0.22 2.61E-01 
CB1 cannabinoid receptor-interacting 
protein 1 
Cnrip1 48.7 10.9 0.22 1.16E-01 
Ubiquitin-like modifier-activating 
enzyme 1 
Uba1 48.7 10.9 0.22 1.16E-01 
Pyruvate dehydrogenase protein X 
component, mitochondrial 
Pdhx 34.0 8.1 0.24 2.86E-01 
Sodium- and chloride-dependent 
GABA transporter 1 
Slc6a1 27.9 7.4 0.26 2.91E-01 
T-complex protein 1 subunit beta Cct2 27.9 7.6 0.27 2.98E-01 
Guanine nucleotide-binding protein 
G(z) subunit alpha 
Gnaz 27.9 7.6 0.27 2.98E-01 
Serine/arginine-rich splicing factor 2 Srsf2 82.7 22.5 0.27 1.66E-01 
Arginase-1  Arg1 29.4 8.1 0.27 2.99E-01 
Actin, alpha cardiac muscle 1 Actc1 165.6 45.5 0.27 3.04E-01 
Prohibitin-2 Phb2 159.2 45.5 0.29 5.40E-02 
Eukaryotic initiation factor 4A-II Eif4a2 113.6 33.2 0.29 2.29E-02 
Ubiquitin carboxyl-terminal hydrolase 
isozyme L1 
Uchl1 76.6 23.0 0.30 7.55E-03 
Isoform 2 of AP2-associated protein 
kinase 1 
Aak1 34.0 10.9 0.32 3.59E-01 
Heterogeneous nuclear 
ribonucleoprotein U-like protein 2 
Hnrnpul2 34.0 10.9 0.32 3.59E-01 
Ras-related protein Rab-10 Rab10 57.3 18.9 0.33 1.99E-01 
Heterogeneous nuclear 
ribonucleoprotein K 
Hnrnpk 138.4 46.0 0.33 1.11E-01 
Atlastin-1 Atl1 90.4 30.1 0.33 3.44E-01 
14-3-3 protein gamma Ywhag 157.8 52.8 0.33 1.20E-01 
60S ribosomal protein L31 Rpl31 63.4 21.7 0.34 1.17E-01 
Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase complex, 
mitochondrial 
Dlat 78.1 27.0 0.35 5.82E-02 
AP-2 complex subunit mu Ap2m1 134.5 48.6 0.36 1.35E-01 
Dynein light chain 1, cytoplasmic  Dynll1 29.4 10.9 0.37 3.93E-01 
Septin-8 Sept8 48.7 18.2 0.37 1.90E-01 
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Solute carrier family 2, facilitated 
glucose transporter member 3 
Slc2a3 69.5 26.3 0.38 2.77E-01 
Mitochondrial 2-oxoglutarate/malate 
carrier protein  
Slc25a11 35.5 14.7 0.41 4.49E-01 
Actin-related protein 2/3 complex 
subunit 4 
Arpc4 91.3 37.9 0.41 8.40E-02 
Protein RUFY3 Rufy3 61.9 26.0 0.42 2.39E-01 
Glycogen synthase kinase-3 beta Gsk3b 42.6 18.2 0.43 2.24E-01 
14-3-3 protein eta Ywhah 107.5 46.2 0.43 1.14E-01 
Ubiquitin-40S ribosomal protein S27a  Rps27a 50.2 21.7 0.43 4.69E-01 
Clathrin coat assembly protein AP180 Snap91 76.6 33.9 0.44 1.05E-02 
T-complex protein 1 subunit zeta-2 Cct6b 34.0 15.4 0.45 4.40E-01 
40S ribosomal protein S14  Rps14 50.2 23.0 0.46 2.08E-01 
Guanine nucleotide-binding protein 
G(i) subunit alpha-2 
Gnai2 188.7 91.4 0.48 2.16E-02 
Dihydropyrimidinase-related protein 
3 
Dpysl3 250.5 125.3 0.50 3.31E-02 
Serine/arginine-rich splicing factor 4 Srsf4 57.3 29.1 0.51 5.66E-01 
MOG-alpha-2 Mog 61.9 31.5 0.51 3.83E-01 
Serine/threonine-protein kinase 
DCLK1 
Dclk1 109.0 58.7 0.54 3.97E-01 
Sodium/potassium-transporting 
ATPase subunit beta-2 
Atp1b2 41.0 22.8 0.56 5.55E-01 
Isocitrate dehydrogenase [NAD] 
subunit gamma 1, mitochondrial 
Idh3g 27.9 15.6 0.56 5.33E-01 
Secretory carrier-associated 
membrane protein 5 
Scamp5 27.9 15.6 0.56 5.33E-01 
Ras-related protein Rab-3C Rab3c 140.0 78.6 0.56 2.88E-01 
14-3-3 protein beta/alpha Ywhab 70.4 40.9 0.58 5.55E-01 
Pyridoxal kinase Pdxk 39.5 23.2 0.59 7.13E-01 
Splicing factor U2AF 65 kDa subunit U2af2 63.4 37.4 0.59 3.13E-01 
Voltage-dependent anion-selective 
channel protein 3 
Vdac3 68.0 40.7 0.60 5.54E-01 
Cytochrome b-c1 complex subunit 
Rieske, mitochondrial 
Uqcrfs1 48.7 30.3 0.62 4.21E-01 
40S ribosomal protein S3 Rps3 97.4 60.9 0.63 3.14E-01 
Transcriptional activator protein Pur-
beta 
Purb 106.0 67.5 0.64 2.29E-01 
Sodium/potassium-transporting 
ATPase subunit beta-1 
Atp1b1 125.3 80.1 0.64 1.86E-01 
Succinyl-CoA ligase [ADP/GDP-
forming] subunit alpha, 
mitochondrial 
Suclg1 55.7 36.7 0.66 5.24E-01 
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Heterogeneous nuclear 
ribonucleoprotein U 
Hnrnpu 205.8 137.7 0.67 4.23E-01 
Hexokinase 1, isoform CRA_f Hk1 218.1 150.4 0.69 1.31E-01 
Destrin Dstn 48.7 34.1 0.70 5.26E-01 
V-type proton ATPase subunit G 2 Atp6v1g2 42.6 30.3 0.71 7.02E-01 
Cell cycle exit and neuronal 
differentiation protein 1 
Cend1 63.4 46.0 0.73 3.40E-01 
Phosphate carrier protein, 
mitochondrial 
Slc25a3 98.9 71.8 0.73 3.87E-01 
Ras-related protein Rab-5A  Rab5a 41.7 30.3 0.73 8.03E-01 
F-actin-capping protein subunit beta Capzb 42.6 31.1 0.73 5.75E-01 
Isoform 3 of Serine racemase Srr 41.0 30.3 0.74 7.18E-01 
Voltage-dependent anion-selective 
channel protein 1  
Vdac1 20.8 15.4 0.74 8.19E-01 
Tubulin alpha-1B chain Tuba1b 600.0 445.5 0.74 1.08E-01 
GTP-binding protein Di-Ras2 Diras2 76.6 59.7 0.78 5.78E-01 
40S ribosomal protein S26 Rps26 27.9 21.7 0.78 8.29E-01 
Ras-related protein Rab-6B  Rab6b 58.8 46.4 0.79 8.57E-01 
D-beta-hydroxybutyrate 
dehydrogenase, mitochondrial 
Bdh1 42.6 33.9 0.80 5.74E-01 
LanC-like protein 2 Lancl2 89.7 71.6 0.80 5.46E-01 
Neuronal membrane glycoprotein 
M6-a 
Gpm6a 57.3 46.0 0.80 7.06E-01 
Activator of 90 kDa heat shock 
protein ATPase homolog 1 
Ahsa1 27.9 23.0 0.83 7.94E-01 
Peroxiredoxin-2 Prdx2 98.9 82.7 0.84 5.77E-01 
Cds2 protein Cds2 48.7 41.2 0.85 7.03E-01 
AP-2 complex subunit beta Ap2b1 110.6 96.3 0.87 8.39E-01 
Tubulin beta-6 chain Tubb6 409.2 357.6 0.87 1.55E-01 
Tubulin beta-5 chain Tubb5 836.8 731.4 0.87 3.50E-01 
AP-3 complex subunit sigma-1  Ap3s1 20.8 18.2 0.87 9.15E-01 
Ras-related protein Rab-3D  Rab3d 58.8 51.6 0.88 8.58E-01 
Calcium-binding mitochondrial carrier 
protein Aralar1 
Slc25a12 249.0 218.9 0.88 7.41E-01 
Tubulin beta-3 chain Tubb3 706.9 668.2 0.95 5.37E-01 
WD repeat-containing protein 37 Wdr37 47.1 44.7 0.95 9.40E-01 
60S ribosomal protein L27  Rpl27 35.5 33.9 0.95 9.40E-01 
Isoform Short of Serine/arginine-rich 
splicing factor 3 
Srsf3 70.4 67.7 0.96 9.25E-01 
MCG2872, isoform CRA_b  Ddx5 42.6 41.4 0.97 9.70E-01 
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Guanine nucleotide-binding protein 
G(i) subunit alpha-1 
Gnai1 102.0 99.3 0.97 9.71E-01 
Solute carrier family 2, facilitated 
glucose transporter member 1  
Slc2a1 41.7 41.4 0.99 9.96E-01 
P301L MAPT (0N4R) Mapt 1000.0 1000.0 1.00 1.00E+00 
Serine/threonine-protein 
phosphatase 2B catalytic subunit 
alpha isoform 
Ppp3ca 185.6 192.5 1.04 9.13E-01 
Pleiotrophin  Ptn 14.7 15.4 1.05 9.68E-01 
Cofilin-1 Cfl1 120.7 132.6 1.10 6.10E-01 
CaM kinase-like vesicle-associated 
protein 
Camkv 117.6 130.5 1.11 8.33E-01 
6-phosphofructokinase, liver type Pfkl 146.1 162.8 1.11 7.79E-01 
GTP-binding nuclear protein Ran Ran 54.2 60.7 1.12 8.88E-01 
Synaptojanin-1 Synj1 63.4 72.6 1.14 8.97E-01 
Elongation factor 1-alpha 1 Eef1a1 130.7 155.2 1.19 6.22E-01 
Synaptogyrin-3 Syngr3 41.0 49.3 1.20 7.67E-01 
60S ribosomal protein L11 Rpl11 27.9 33.9 1.22 7.28E-01 
ADP/ATP translocase 2 Slc25a5 126.8 158.4 1.25 7.71E-02 
Sodium- and chloride-dependent 
GABA transporter 3 
Slc6a11 26.3 34.4 1.31 7.95E-01 
F-actin-capping protein subunit 
alpha-2 
Capza2 63.4 85.3 1.35 6.31E-01 
Protein Prps1l3 Prps1l3 13.2 18.2 1.38 7.77E-01 
6-phosphofructokinase Pfkp 146.1 202.7 1.39 3.04E-01 
Mitochondrial glutamate carrier 1  Slc25a22 35.5 49.5 1.39 5.60E-01 
Protein Rap1gds1 Rap1gds1 13.2 18.4 1.40 7.68E-01 
Sarcoplasmic/endoplasmic reticulum 
calcium ATPase 2 
Atp2a2 231.2 333.9 1.44 2.97E-01 
Sideroflexin-1  Sfxn1 14.7 22.3 1.52 7.23E-01 
Glutaminase kidney isoform, 
mitochondrial 
Gls 34.0 51.6 1.52 5.47E-01 
Ras-related protein Rab-1B  Rab1b 14.7 22.8 1.55 7.07E-01 
60 kDa heat shock protein, 
mitochondrial 
Hspd1 26.3 41.4 1.57 5.99E-01 
Microtubule-associated protein 
RP/EB family member 2 
Mapre2 13.2 22.8 1.73 6.37E-01 
Isoform 2 of Elongation factor Tu, 
mitochondrial  
Tufm 71.1 123.2 1.73 2.58E-01 
Cytoplasmic FMR1-interacting protein 
2  
Cyfip2 35.5 61.7 1.74 6.59E-01 
Isoform 2 of cAMP-dependent 
protein kinase catalytic subunit alpha 
Prkaca 13.2 23.0 1.75 5.43E-01 
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4F2 cell-surface antigen heavy chain Slc3a2 81.1 145.9 1.80 3.05E-01 
Beta-soluble NSF attachment protein Napb 41.0 74.6 1.82 2.94E-01 
Cyclin-dependent kinase 5 Cdk5 61.9 119.8 1.94 9.75E-02 
ADP/ATP translocase 1 Slc25a4 112.1 226.4 2.02 4.21E-02 
Alpha-centractin Actr1a 55.7 114.3 2.05 2.94E-01 
Protein kinase C gamma type Prkcg 81.1 167.8 2.07 2.39E-01 
T-complex protein 1 subunit epsilon  Cct5 20.8 44.2 2.12 4.37E-01 
Dynactin subunit 2 Dctn2 133.8 306.5 2.29 2.25E-03 
ADP-ribosylation factor-like protein 
8A  
Arl8a 14.7 34.4 2.34 3.64E-01 
Isoform 2 of T-complex protein 1 
subunit alpha 
Tcp1 48.7 115.6 2.37 6.76E-02 
Synaptic vesicle glycoprotein 2B Sv2b 42.6 104.9 2.46 1.43E-01 
Vacuolar protein sorting-associated 
protein 35 
Vps35 13.2 33.2 2.52 3.13E-01 
6-phosphofructokinase, muscle type Pfkm 117.6 302.5 2.57 2.24E-03 
Poly(rC)-binding protein 1 Pcbp1 13.2 35.1 2.66 4.40E-01 
T-complex protein 1 subunit gamma Cct3 13.2 36.4 2.77 3.96E-01 
Claudin-11  Cldn11 14.7 41.2 2.80 1.51E-01 
ADP-ribosylation factor 4 Arf4 27.9 83.9 3.01 1.38E-01 
Dynactin subunit 3  Dctn3 14.7 48.8 3.32 7.96E-02 
cGMP-dependent 3',5'-cyclic 
phosphodiesterase 
Pde2a 13.2 44.7 3.40 1.53E-01 
Dual specificity mitogen-activated 
protein kinase kinase 1 
Map2k1 27.9 101.8 3.65 1.74E-02 
Protein Slc8a2  Slc8a2 50.2 186.5 3.71 5.41E-02 
Isoform HSP105-beta of Heat shock 
protein 105 kDa 
Hsph1 153.1 665.0 4.34 5.47E-04 
Isoform 2 of Neurochondrin Ncdn 47.1 218.8 4.64 1.90E-03 
Isoform B of AP-2 complex subunit 
alpha-1  
Ap2a1 29.4 148.4 5.05 5.72E-02 
Serine/threonine-protein 
phosphatase 2A 55 kDa regulatory 
subunit B alpha isoform  
Ppp2r2a 35.5 181.5 5.11 1.34E-02 
Beta-centractin Actr1b 26.3 138.2 5.25 1.01E-01 
Mitogen-activated protein kinase 1 Mapk1 13.2 69.7 5.30 1.11E-01 
Neurofilament medium polypeptide  Nefm 20.8 169.0 8.11 3.98E-02 
Clathrin heavy chain 1  Cltc 109.1 900.3 8.25 5.32E-04 
Puromycin-sensitive aminopeptidase Npepps 13.2 112.5 8.55 6.59E-03 
Glycogen phosphorylase, brain form Pygb 27.9 240.8 8.64 3.14E-03 
Heat shock 70 kDa protein 4L Hspa4l 13.2 338.5 25.73 8.07E-03 
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Actin-related protein 10  Actr10 0.0 30.6 #DIV/0! 4.86E-02 
AP-3 complex subunit beta-2  Ap3b2 0.0 58.9 #DIV/0! 1.82E-01 
Protein Atp2b3  Atp2b3 0.0 199.7 #DIV/0! 4.76E-02 
ATPase, Ca++ transporting, plasma 
membrane 4  
Atp2b4 0.0 224.1 #DIV/0! 6.23E-02 
Isoform 3 of Calcium/calmodulin-
dependent protein kinase type II 
subunit gamma  
Camk2g 0.0 84.4 #DIV/0! 1.35E-01 
Cullin-associated NEDD8-dissociated 
protein 1  
Cand1 0.0 40.7 #DIV/0! 2.36E-01 
CDP-diacylglycerol--inositol 3-
phosphatidyltransferase  
Cdipt 0.0 15.6 #DIV/0! 1.34E-01 
Centrosomal protein of 152 kDa  Cep152 0.0 33.9 #DIV/0! 4.66E-05 
Copine-6  Cpne6 0.0 18.9 #DIV/0! 1.41E-01 
Isoform 3 of C-terminal-binding 
protein 1  
Ctbp1 0.0 22.5 #DIV/0! 1.71E-01 
Isoform 6 of Serine/threonine-
protein kinase DCLK2  
Dclk2 0.0 18.4 #DIV/0! 1.44E-01 
Isoform 2 of Dynactin subunit 4  Dctn4 0.0 121.6 #DIV/0! 3.17E-02 
ATP-dependent RNA helicase DDX3Y  Ddx3y 0.0 15.4 #DIV/0! 1.35E-01 
DIS3-like exonuclease 2  Dis3l2 0.0 15.6 #DIV/0! 1.34E-01 
Isoform 5 of Dynamin-1-like protein  Dnm1l 0.0 40.7 #DIV/0! 2.36E-01 
Isoform 4 of Engulfment and cell 
motility protein 1  
Elmo1 0.0 15.6 #DIV/0! 1.34E-01 
RNA-binding protein EWS  Ewsr1 0.0 56.1 #DIV/0! 3.66E-03 
Isoform 2 of Glial fibrillary acidic 
protein  
Gfap 0.0 323.5 #DIV/0! 3.57E-03 
Heterogeneous nuclear 
ribonucleoprotein A0  
Hnrnpa0 0.0 23.0 #DIV/0! 2.43E-02 
17beta-hydroxysteroid 
dehydrogenase type 10/short chain 
L-3-hydroxyacyl-CoA dehydrogenase  
Hsd17b10 0.0 15.4 #DIV/0! 1.35E-01 
Heat shock 70 kDa protein 1A  Hspa1a 0.0 118.6 #DIV/0! 4.79E-02 
Heat shock 70 kDa protein 1-like  Hspa1l 0.0 96.8 #DIV/0! 1.05E-02 
Heat shock-related 70 kDa protein 2  Hspa2 0.0 141.6 #DIV/0! 4.08E-02 
Heat shock 70 kDa protein 4  Hspa4 0.0 193.6 #DIV/0! 1.05E-02 
Isoform 2 of Isocitrate 
dehydrogenase [NAD] subunit alpha, 
mitochondrial  
Idh3a 0.0 23.2 #DIV/0! 1.63E-01 
Trans-L-3-hydroxyproline 
dehydratase  
L3hypdh 0.0 14.9 #DIV/0! 1.34E-01 
Mitogen-activated protein kinase 15  Mapk15 0.0 18.2 #DIV/0! 1.46E-01 
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Isoform 2 of Calcium uniporter 
protein, mitochondrial  
Mcu 0.0 14.9 #DIV/0! 1.34E-01 
Isoform 2 of Nck-associated protein 
1  
Nckap1 0.0 25.8 #DIV/0! 3.08E-02 
Poly(rC)-binding protein 3  Pcbp3 0.0 33.6 #DIV/0! 3.56E-02 
Protein phosphatase 1E  Ppm1e 0.0 63.7 #DIV/0! 3.63E-02 
Serine/threonine-protein 
phosphatase 2A catalytic subunit 
alpha isoform  
Ppp2ca 0.0 55.5 #DIV/0! 1.95E-01 
Serine/threonine-protein 
phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform  
Ppp2r1a 0.0 188.3 #DIV/0! 4.89E-06 
Serine/threonine-protein 
phosphatase  
Ppp3cb 0.0 79.5 #DIV/0! 2.92E-02 
Phosphorylase  Pygm 0.0 29.3 #DIV/0! 2.03E-01 
Ras-related protein Rab-1A  Rab1 0.0 45.5 #DIV/0! 1.60E-01 
Ras-related protein Rap-2b  Rap2b 0.0 22.3 #DIV/0! 1.66E-01 
RNA binding motif protein, X-linked-
like-1  
Rbmxl1 0.0 99.3 #DIV/0! 2.53E-02 
Transforming protein RhoA  Rhoa 0.0 23.0 #DIV/0! 2.43E-02 
Rho-related GTP-binding protein 
RhoG  
Rhog 0.0 37.4 #DIV/0! 8.45E-02 
Sideroflexin-5  Sfxn5 0.0 15.4 #DIV/0! 1.35E-01 
Isoform 2 of Solute carrier family 12 
member 5  
Slc12a5 0.0 167.1 #DIV/0! 1.78E-02 
Monocarboxylate transporter 1  Slc16a1 0.0 29.9 #DIV/0! 1.34E-01 
Vesicular glutamate transporter 1  Slc17a7 0.0 90.7 #DIV/0! 1.29E-08 
Isoform 7 of Synaptotagmin-like 
protein 2  
Sytl2 0.0 15.6 #DIV/0! 1.34E-01 
Protein Taf15  Taf15 0.0 22.5 #DIV/0! 1.71E-01 
Tubulin polymerization-promoting 
protein  
Tppp 0.0 15.4 #DIV/0! 1.35E-01 
Tubulin alpha-1A chain  Tuba1a 0.0 307.2 #DIV/0! 2.59E-02 
Ubiquitin carboxyl-terminal hydrolase  Usp5 0.0 18.2 #DIV/0! 1.46E-01 
Isoform 2 of WD repeat-containing 
protein 7  
Wdr7 0.0 48.0 #DIV/0! 1.42E-01 
14-3-3 protein epsilon  Ywhae 0.0 54.5 #DIV/0! 1.38E-01 
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